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1. Introduction 
The gold standard for the treatment of ascending aortic and aortic arch aneurysms, dissection 
and advanced aortic calcification is still surgery. In the last 30 years, the mortality and 
morbidity of such operations have significantly decreased. However, according to most of the 
studies, the occurrence of postoperative acute kidney injury (AKI) is a frequent and severe 
postoperative complication of cardiac surgery, particularly when a hypothermic circulatory 
arrest (HCA) and cardiopulmonary bypass (CPB) are used.  
HCA has been shown to have adverse effects on multiple organ systems(1). Postoperative AKI 
is a common complication (40–50%) encountered in patients undergoing thoracic aorta 
replacement under HCA(2-3). 
CPB was considered according to many studies to be the second most common cause of AKI 
in the intensive care unit after sepsis(4). 
AKI represents a significant factor influencing 30 day and long-term outcome and is 
associated with a high incidence of morbidity and mortality as it places the patients at 5-times 
higher mortality risk during the hospital stay. The incidence of AKI varies with the causative 
aetiology, which differs according to the surgical techniques, perioperative management and 
pharmacological therapy used. However, we now understand better those different aetiologies 
of the underlying problem. Despite successful strategies to provide sufficient renal protection 
or strategies for ‘rescue therapy’, they are either unsubstantiated by randomised clinical trials 
or show no signiﬁcant efﬁcacy. 
The early identification and therapeutic intervention for those individuals at high risk of 
developing post cardiac surgery – acute kidney injury (PCS-AKI) are critical to optimising the 
outcomes. In this analysis, we collected data for the last 15 years from approximately 1400 
patients who underwent aortic ascending and aortic arch replacement using HCA and CPB. 
In this study, we evaluate the correlation between outcome and AKI using serial preoperative, 
intraoperative and postoperative creatinine, urea and glomerular filtration rate (GFR) controls.  
We also clear different surgical techniques as the HCA and CPB that were used and their 
influence on the perioperative kidney function. In addition to that we clear as well the various 
definitions, prevention strategies, early detection methods (novel markers and prediction 
scores before and after the operation), and risk factors, as well as causes of AKI. 
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1.1 Background of acute kidney injury 
 
1.1.1 Definition of acute kidney injury 
 
In the last few years, many studies and research papers have arisen with different definitions 
of acute kidney injury (5,6,7); although they have defined AKI differently from each other, there 
was a general criterion to define AKI which is: 
“A sudden loss or decrease in kidney function that is manifested clinically by signs including 
a rapid decline in the glomerular filtration rate (GFR), resulting in the dysregulation of 
extracellular fluid-, electrolyte- and acid-base balance, the retention and accumulation of urea 
and other nitrogenous waste products in the circulation (azotemia) and often low urine output 
(oliguria or anuria). In severe cases, this leads to metabolic acidosis, severe fluid retention, 
and electrolyte disturbance, as well as hypertension, and might require renal replacement 
therapy, traditionally in the form of intermittent haemodialysis." 
 
There was confusion about the best way to evaluate and classify kidney functions, including 
which markers reflect them and which values of those markers indicate normal and abnormal 
kidney functions until the Acute Dialysis Quality Initiative (ADQI) created the RIFLE 
criteria(4) (an acronym for Risk, Injury, Failure, Loss of kidney function, and End-stage kidney 
disease). More recently, the AKIN criteria(5) (Acute Kidney Injury Network) and the KDIGO 
criteria(6) (Kidney Disease Improving Global Outcomes) were developed based on the RIFLE 
criteria. Therefore, the three classifications look similar at first sight. In all three classification 
systems, we can grade the AKI according to the increase in serum creatinine (SCr) or the 
duration of oliguria.  
 
1.1.2 Aetiology of acute kidney injury  
 
The aetiology of AKI has traditionally been classified into three categories (A) post-renal, 
(B) intrinsic or renal and (C) pre-renal factors. These classifications provide practical 
information about the different pathophysiological aetiologies that underlines AKI. 
  
(A) Post-renal AKI 
Post-renal failure is caused by clinical conditions which cause urine outflow obstruction due 
to:  
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• Bilateral renal tubule obstruction 
• Bilateral ureteric obstruction.  
• Unilateral ureteric or renal tubule obstruction with a non-functioning or missing 
another kidney. 
• Urethral obstruction with subsequent blockage of the urine pathway. 
 
Any factor that obstructs urine excretion may cause this type of renal injury by increasing the 
intra-tubular pressure and thus decreasing GFR(8). Also, acute urinary tract obstruction can 
lead to impaired renal blood flow and inflammatory processes that also contribute to 
diminished GFR(9).  
If the post-renal injury is not treated rapidly, it may result in either temporary or permanent 
actual nephron damage as well as resultant intrinsic renal injury.  
 
(B) Intrinsic AKI (renal parenchymal disease) 
This is caused by injury of the major structural components of the kidney, such as nephrons 
and renal parenchyma. Causes include:  
 Acute tubular necrosis (ATN): Tubular damage is the most common underlying cause 
of intrinsic AKI occurring after surgery either because of ischaemic or nephrotoxic reasons 
(10). 
 Acute interstitial nephritis.  
 Acute severe pyelonephritis which leads to papillary necrosis, e.g. in Diabetes mellitus  
 Rapidly progressive glomerulonephritis.  
 Malignant hypertension or athero-embolic renal disease => Leading to vasculopathies 
which induce damage to the renal vasculature. 
   
(C) Pre-renal AKI is caused by a significant reduction in kidney perfusion. The kidney, 
which has the highest tissue perfusion rate relative to organ weight, typically receives 15–
20% of the total cardiac output (11). This high perfusion rate makes the kidney vulnerable to 
haemodynamic injury. General causes that decrease kidney perfusion or alter the renal 
haemodynamics include:  
 Hypovolemia as in blood, plasma or fluids loss. 
 Shock with normal intravascular volume as in cardiogenic shock or Massive 
pulmonary embolism. 
4 
 
 
 Others: third spacing, e.g. pancreatitis, hepato-renal syndrome. 
 Pre-renal AKI is reversible after correction of the underlying cause in the presence of 
normal kidney parenchyma and tubules, but when the duration of AKI induced by a prerenal 
cause is prolonged without rapid intervention, renal parenchymal damage occurs, eventually 
giving rise to intrinsic kidney injury(12), and in severe causes irreversible cortical necrosis 
happened(13). 
Surgeries required CPB procedures were found to be one of the most common causes of 
postoperative prerenal AKI(13,14,16). Other more controversial, but potentially significant 
modifiable risk factors are those specifically related to the performance of CPB, such as on-
pump versus off-pump technique, pulsatile versus non-pulsatile flow, normothermic versus 
hypothermic CPB, haemodilution during CPB, and the duration of CPB(15). These factors are 
discussed in more detail later in this review. 
 
1.1.3 Classification of acute kidney injury 
 
1.1.3.1  KDIGO Classification and definition of AKI (Figure 1)(17) 
Recently, in 2012, the AKI study group called “Kidney Disease Improving Global Outcomes 
(KDIGO)” modified a new definition that combines the differences between the RIFLE and 
AKIN definitions; AKI is defined by the KDIGO as any of the following:  
(A)  increase in SCr by ≥0.3 mg/dl within 48 hours or 
(B)  increase in SCr to ≥1.5-times the baseline within seven days or  
(C)  Reduction in urine output <0.5 ml/kg/h for 6 hours. 
(D) Treatment with renal replacement therapy (direct stage 3)  
 
Stage Serum Creatinine criteria Urine output criteria 
 
Stage 1 
 
Increase in SCr by ≥0.3 mg/dl (≥26.5μmol/l) within 48 
hours or  
Increase in SCr to ≥1.5- to 1.9-times the baseline within 
seven days  
 
 
Urine output <0.5 ml/kg/h for 6–12 h 
 
 
Stage 2 
 
 
Increase of serum creatinine to 2.0 – 2.9 times from baseline 
 
 
Urine output <0.5 ml/kg/h for ≥ 12 h 
 
 
Stage 3 
 
 
Increase of serum creatinine ≥3.0 times from baseline or 
serum creatinine ≥4.0 mg/dl (≥354 μmol/L) or 
treatment with RRT or 
in patients <18 years, a decrease in estimated GFR to <35 
ml/min per 1.73 m² 
 
 
Urine output <0.3 ml/kg/h for ≥24 h 
or 
anuria for ≥12 h 
 
Figure 1: KDIGO Classification, GFR: glomerular filtration rate; SCr,: serum creatinine. 
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In the RIFLE and KDIGO, “acute on top of chronic AKI” is defined as a separate AKI stage 
(SCr ≥4 mg/dl ± a sharp rise of 0.5mg/dl) BUT; AKIN Classifies acute on chronic AKI as a 
part of stage 3.  
 
1.1.4 Pathophysiology of PCS-AKI with moderate HCA and CPB 
 
AKI is a common post cardiac surgery complication that affects up to 30% of patients (18), 3% 
of which require RRT (19,20,21). 
Cardiac surgery with CPB is the second most common cause of AKI in ICU after sepsis and is 
independently associated with short- and long-term morbidity and mortality (22). 
Many studies have demonstrated that the overall mortality after cardiac surgery ranges from 
1% to 8%, but when AKI complicates surgery, a four-fold increase in the risk of death has 
been observed (23). Moreover, the mortality of patients requiring RRT increases to 63%(24). 
Furthermore, according to a recent retrospective study of 2973 patients, 45% of post-cardiac 
surgery patients surviving RRT remain dialysis-dependent, 33% may have partial renal 
recovery, and only 21% may have a complete renal recovery at the time of hospital 
discharge(25). 
The commonest cause of postoperative AKI with HCA/CPB-surgery is ATN as a result of 
ischemic injury to nephrons in the medullary region of the kidney secondary to hypotension, 
hypovolaemia, and/or dehydration. However, several recent studies have identified some 
covariates affecting renal function in different pathways and proved that the underlying cause 
is multi-factorial rather than only being related to the kidney haemodynamic alterations(26). 
 
Those predisposing factors are divided according to the time course of the operation into pre-, 
intra- and post-operative (27) summarised in Table 1. 
 
Table 1: Factors Associated with postoperative AKI (27) 
 
 
 
Preoperative Intraoperative Postoperative 
 
- Nephrotoxic drugs 
- Inflammation 
- Underlying CKD 
- Decreased effective volume 
- Renovascular disease 
- Congestive heart failure 
 
- Cardiopulmonary bypass 
- Anaemia 
- Embolic events 
- Haemodilution 
- Shock 
 
- Decreased cardiac function 
- Vasoactive drugs 
- Nephrotoxic drugs 
- Unstable hemodynamic state 
- Inflammation 
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1.1.4.1  The common associated risk factors and predictive scores 
 
- Predictive scores 
The accurate prediction of postoperative-AKI provides clinicians with the chance to apply 
efficient prophylactic and therapeutic measures as early as possible. Several risk stratification 
systems exist for cardiac surgery patients.  
 
The best-validated scores predict severe AKI requiring RRT (dialysis) after cardiac surgery 
include the (A) Cleveland Clinic Score and (B) the Mehta Score (20,28) and more recently 
(c) the Simplified Renal Index (SRI) score 
 
(a) In 2005, Thakar et al.(28) published the Cleveland Clinic Score with a high level of 
precision in the calculation of the prevalence of PCS-RRT. After studying 33,217 patients 
who underwent open-heart surgery at the Cleveland Clinic Foundation between 1993 and 
2002, the primary outcome was to identify high risk-AKI liable-patients who might require 
postoperative RRT (Figure 2). 
 
(b) In 2006, Mehta et al.(20) suggested a bedside tool (Mehta score) for predicting the risk 
based on eight preoperative variables in 86,009 patients 
 
(c) In 2007, Wijeysundera et al.(21) established the SRI model (SRI score, Toronto). 
 
Risk factor Points 
Female gender 1 
Congestive heart failure 1 
Left ventricular ejection fraction <35% 1 
Preoperative use of IABP 2 
COPD 1 
Insulin-requiring Diabetes 1 
Previous cardiac surgery 1 
Emergency surgery 2 
Valve surgery only (reference to CABG) 1 
CABG+ valve (reference to CABG) 2 
Other cardiac surgery 2 
Preoperative creatinine 1.2 to 2.1 mg/dl 
 
2 
Preoperative creatinine >2.1 
 
5 
Figure 2; The Thakar score(28). (Minimum score 0; maximum score 17). 
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Table 2; Comparison between the three RRT prediction scores  
Score (range)  Thakar (0-17) Mehta (5-83) Simplif (0-8) 
 
Demographics     
-Age (12.0%)    0-10 (12.0%)  
-Female 1 (5.9%)   
-Race:  2 (2.4%)  
Preoperative history     
-Chronic lung disease  1 (5.9%) 3 (3.6%)  
-Diabetes controlled orally 
/diabetes insulin-dependent  
 
1 (5.9%) 
2 (2.4%) 
5 (6.0%) 
1 (12.5%) 
-Basal creatinine 2-5 (29.4%) 5-40 (48.2%)  
-eGFR   1-2 (25%) 
Preoperative cardiac status     
-Congestive heart failure  1 (5.9%)   
-LVEF  1 (5.9%)  1 (12.5%) 
-Myocardial infarction <3 wks   3 (3.6%)  
-Cardiogenic shock  7 (8.4%)  
-NYHA class IV   3 (3.6%)  
-Preoperative use of IABP 2  2 (11.8%)  1 (12.5%) 
-Previous cardiac surgery 1 (5.9%) 3 (3.6%) 1 (12.5%) 
Operative details     
-Surgery type (CABG/Valve)  1-2 (11.8%) 2-7 (8.4% 1 (12.5%) 
-Emergent surgery 2 (11.8%  1 (12.5%) 
 
These scores use similar risk factors to predict AKI. However, external validation studies 
have been performed (29,30), with findings that the Cleveland scoring system offered the best 
discriminative value for postoperative RRT. However, before using a model to estimate risk 
probabilities at a specific centre, recalibration may be needed. 
The prediction of mild and moderate AKI is also essential (17). That is why Birnie et al.(31) 
analysed data collected prospectively from over 30,000 subjects undergoing cardiac surgery at 
three British hospitals to develop the first prediction model for all stages of postoperative-AKI 
using the KDIGO criteria. The model’s risk prediction score for any stage of AKI (AUC, 0.74 
(95% CI: 0.72–0.76)) demonstrated better discrimination than the Cleveland Clinic Score 
and equivalent discrimination to the Mehta score.  
 
The incorporation of novel markers into prediction scores may provide additional 
opportunities to identify patients at high risk. Until now, most studies have evaluated the 
ability of damage and functional markers to predict AKI compared with clinical risk 
factors. However, to date, they are not used in any prediction scores for postoperative 
AKI. 
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- Risk factors: 
Some recent patient-related and surgery-related studies have emphasised the risk factors 
involved in cardiac-surgery and vascular-surgery-associated AKI (Table 3) (20,23,24,32-36). 
 
Table 3: Risk factors for AKI after cardiac (I) and vascular-open (II) surgeries  
 Cardiac surgery (20,23,24,32-36) 
 Female sex 
 Cardiogenic shock 
 NYHA class IV 
 Reduced LV function 
 Congestive heart failure 
 Preoperative need for IABP 
 Diabetes mellitus 
 Peripheral vascular disease 
 COPD 
 Preoperative reduced renal function (eGFR<60 mL/min; Cr >2.1 mg/dL) 
 Anaemia (Hb <12.5 g/dL) 
 Emergent surgery 
 Re-intervention 
 Intraoperative use of aprotinin 
 CPB time 
 Cross-clamp time 
 Transfusions (PRBC) 
 Haemodilution 
 Valve or combined (Valve and CABG) surgery 
 Haemolysis 
 Recent exposure to nephrotoxic agents (such as radio-contrast dyes, bile pigments, 
aminoglycoside antibiotics, and NSAIDs) 
 Respiratory disease 
 Advanced age 
 African-American ethnicity 
 Increased body weight 
 Pulse pressure hypertension 
 Poor intraoperative blood pressure control 
 Aortic surgery 
 
 
 Vascular surgery-open(37-39) 
 Renal ischaemia (aortic cross clamp time) 
 Double renal ischaemia vs. single ischaemia 
 Intraoperative hypotension 
 Age 
 Symptomatic AAA 
 Supra/iuxtrarenal AAA 
 Preoperative SCr >1.5 mg/dL 
 Hypertension 
 Respiratory disease 
 
AAA: abdominal aortic aneurysm; CABG: coronary artery bypass surgery; CAD: coronary artery disease;  
COPD: chronic obstructive pulmonary disease; CPB: cardiopulmonary bypass; Cr: creatinine; eGFR: estimated 
glomerular filtration rate; Hb: haemoglobin; ; IABP: intra-aortic balloon pump; LV: left ventricle; NYHA: New 
York Heart Association; PRBC: packed red blood cells; SCr: serum creatinine  
 
In our discussion part, each of the previous risk factors, as well as each risk factor in the 
predicting score mentioned above, will be revised and analysed individually to determine 
whether they are correlated to postoperative AKI or not. 
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1.1.5  Postoperative Kidney functions tests 
 
1.1.5.1  Kidney functions tests and “old” biomarkers (widely used until now) 
Although there are different varieties of kidney function, clinically in the ICU, tubular 
metabolism, hormone production and the excretion of small peptides are rarely measured. The 
two physiological functions that are continuously measured in the ICU – and seen to be of 
clinical interest are (1) the excretion of metabolic water-soluble wastes like urea and 
creatinine and (2) urine output. Consequently, these are the aspects of renal function that 
clinicians have focused on to define the presence of acute kidney injury.  
The excretion of metabolic water-soluble wastes is the result of glomerular filtration and the 
glomerular filtration rate (GFR). The standard way to evaluate renal function is measuring the 
clearance of those waste substances (i.e. creatinine clearance). However, GFR varies as a 
function of normal physiology as well as disease. For example, vegetarians may have a GFR 
of 45–50 ml/min, while non-vegetarians with high dietary protein levels may have a GFR of 
140–150 ml/min, although both have a healthy kidney with the same renal mass(40). 
The baseline glomerular filtration rate can be increased by either efferent arteriolar 
vasoconstriction or afferent arteriolar vasodilatation, or both. Angiotensin-converting enzyme 
(ACE) inhibitors induce the opposite effect and reduce GFR(41). The maximum GFR is not yet 
recognised, but it can be approached with an acute high protein or amino acid intake. 
The principle of a baseline and maximal GFR is defined as the “renal functional reserve”. A 
hypothetical patient with a vegetarian diet and another patient with a unilateral nephrectomy 
may have the same baseline GFR, but their functional reserve may be different. Consequently, 
even accurate measurements of baseline GFR may not correspond to the full extent of 
functioning renal mass and will not allow the clinician to define the renal function.  
In the intensive care unit and perioperative, routine measurements of renal clearance are 
taken; standard practice is to estimate the GFR using serum creatinine. Although creatinine 
clearance is known to be the best predictive marker of a change in renal function and the 
possible subsequent development of perioperative dysfunction, the test is not practical in the 
operating theatre, is too unreliable to indicate acute postoperative changes in kidney 
function(42) and is problematic for the following reasons: 
 
• Serum creatinine levels are elevated after renal function has declined about 48 h after 
the initiating event and do not reflect injury, so a considerable proportion of patients with 
normal serum creatinine values may have a reduced GFR, and a reduction of 50% may even 
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be associated with a normal serum creatinine concentrations; therefore, using SCr results in a 
delayed diagnosis of postoperative AKI when in fact severe tubular injury has occurred and 
may be ongoing. 
• It is subject to confounding factors such as age, sex, muscle mass, and diet.  
 
Therefore, recent investigations have focused mainly on finding practical serum and urine 
biomarkers that could reveal early postoperative renal injury before profound functional 
damage occurs; those are called Novel Biomarkers. 
 
1.1.5.2  Novel biomarkers and identification of subclinical postoperative AKI 
Changes in SCr develop late in cases of postoperative AKI, typically 48 h after the initial 
renal injury(43). Haemodilution related to the pump prime is a factor in this. That results in a 
delayed diagnosis of postoperative AKI when in fact severe tubular injury has already 
occurred and may still be ongoing. Thus, one of the critical conditions that influence the 
successful treatment of postoperative AKI, the earlier detection and intervention(44,45), is not 
fulfilled here as interventional therapy would be initiated too late after the acute tubular 
necrosis is already established and ongoing.  
Several research studies (46,47) have suggested that the lack of sensitive “troponin-like” kidney-
biomarkers for the early detection of acute kidney injury has had a negative impact on clinical 
trials investigating promising interventional strategies for AKI(48,49). Therefore, in the last few 
years, the attention of the researchers with regard to AKI was focused on finding novel AKI 
biomarkers. Luckily, it is an area of intense activity (50, 51). 
Publications by Bagshaw, Bellomo, and Devarajan explain the ideal characteristics of AKI 
biomarkers(46,47): 
(1) They should be easy, quick and cheap, and use readily available specimens (i.e. urine, 
serum).  
(2) They should be precise and reliable and use standardised assay methods applied 
merely at the bedside. 
(3) They should be highly sensitive for AKI, thus permitting early detection.  
(4) They should enable monitoring of the course of injury patterns and have some ability 
to predict the severity and trajectory of AKI (i.e. the need for RRT).  
(5) They should be specific, allowing the clinician to discriminate between subtypes of 
AKI.  
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The detection of these novel biomarkers opened up a new era of early detection, intervention, 
and prognosis for AKI. They had a significant effect on enhancing monitoring, the early 
initiation of treatment measures, and improved patient counselling. Those markers are 
proteins released from the kidney in serum during injury and others filtered by them in the 
urine which reflect the glomerular filtration more accurately and offer several theoretical 
advantages over SCr. Concentrations of those biomarkers increase in the plasma and urine 
within a few hours from the injury. Some are more specific, while others are more sensitive. 
Some markers (A) are still under investigation for renal damage (e.g., NGAL, KIM 1, IL-18, 
NAG, and GST) and function (cystatin C).  
Others (B) have recently been approved by the FDA (TIMP-2 and IGFBP-7) and are now 
used as an assessment of the risk of moderate or severe AKI within 12 hours of cardiac 
surgery.  
(A) and (B) will be explained later in the next part of the review. 
(A) Novel biomarkers under investigation 
 
Neutrophil gelatinase-associated lipocalin (NGAL) 
NGAL is a protein found naturally in tissue and circulates at minimal concentrations in the 
blood plasma. It is released from neutrophils into the plasma at higher levels in response to 
inflammation and comprises a critical component of innate immunity to bacterial infection. 
Studies prove that NGAL is one of the most up-regulated proteins in the kidney very early 
after acute injury(52,53), is a highly induced protein in the kidney after ischaemic or 
nephrotoxic AKI and reflects tubular injuries in animal models(54).  
Haase et al.(55) validated these benefits for NGAL when they illustrated the plasma NGAL-
positive but creatinine-negative AKI and correlated that with longer length hospital and ICU 
stays, and a higher risk of dialysis or death. 
However, other studies proved that plasma NGAL was not a useful predictor of AKI within 
the first six hours after cardiac surgery, instead of reflecting systemic inflammation more than 
the extent of a renal injury inflicted(56). However, urinary NGAL was shown to be a highly 
sensitive and specific predictor of cardiac surgery-associated acute kidney injury (PCS-
AKI)(52). It was demonstrated to be an early biomarker of AKI after CPB, increasing 25-fold 
within two hours and declining six hours after surgery(52). This promoted the use of urine 
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NGAL as a predictive indicator of subclinical PCS-AKI; it was also superior to conventional 
markers and plasma NGAL in the early diagnosis of PCS-AKI(57).  
Very recently, in a cohort of high-risk adult patients undergoing cardiac surgery, there was an 
increase in postoperative AKI and 1-year mortality from the first to the third tertile of 
preoperative serum NGAL. Those in the last tertile (>220ng/L) had an estimated two-fold 
increased risk of cardiovascular and all-cause mortality at one-year(58). 
It is certain that once urinary and plasma NGAL are introduced into more clinical 
practice and observational studies, this novel biomarker test will outline their role in our 
investigational and diagnostic field more clearly. Meanwhile, it has excellent potential to 
be used in intervention trials as a way of enriching the study population for the 
randomisation of putative interventions. 
Kidney injury molecule-1 (KIM-1)  
KIM-1 is a type 1 transmembrane glycoprotein that is usually minimally expressed in the 
proximal tubule of the kidney. In cases of ischaemic or nephrotoxic AKI, it is markedly up-
regulated in proximal renal tubular cells⁽59-61⁾. Although fewer cardiac surgery studies on 
KIM-1 have been published, several recent studies reported the sensitivity and increase in 
plasma KIM-1 levels within two days for non-cardiac surgical patients who would develop 
AKI; correspondingly, KIM-1 was suggested as a predictor biomarker for early AKI 
detection(62). In one study that involved 103 adult patients who underwent an operation with 
cardiopulmonary bypass, KIM-1 levels increased markedly at both 2 and 24 hours 
postoperatively in patients who afterwards developed AKI(63). In a recent review, KIM-1 was 
proved to be useful as a diagnostic assay for AKI after cardiac surgery but was less sensitive 
in predicting postoperative mortality or the need for renal replacement therapy (dialysis)(64). 
Interleukin-18 
IL-18 is a pro-inflammatory cytokine and possible mediator of tubular injury. It was shown to 
be significantly increased in a mouse model of ischaemic acute renal failure(66). In humans, 
IL-18 was found in the urine of patients with established AKI when compared to urine from 
patients with urinary tract infection, chronic kidney disease (CKD), so-called pre-renal 
azotaemia and healthy controls(66). A prospective observational study by Parikh et al. 
demonstrated that an increase in IL-18 (and NGAL) in the postoperative period after cardiac 
surgery was predictive of AKI in paediatric patients(67). In a nested case-control study within 
the Acute Respiratory Distress Syndrome (ARDS) Network, IL-18 was demonstrated to 
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precede clinical evidence of AKI by an estimated 24-48 hours(68). The performance of urine 
IL-18, as shown by the area under the receiver operating characteristics curve, for diagnosis 
of AKI at 4, 12, and 24 h after CPB was 61%, 75%, and 73%, respectively(67).  
 
(B) Novel markers recently approved by the US Food and Drug Administration 
 
-Tissue inhibitor of metalloproteinase-2 (TIMP-2)  
-Insulin-like growth factor binding protein 7 (IGFBP7) 
Tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding 
protein 7 (IGFBP7) are cell-cycle arrest proteins. They are released in the urine during events 
of tubular injury due to toxin exposure, hypoxia, and inflammation(69). 
Recently, the FDA has approved the measurement of those two biomarkers to aid in the risk 
assessment of moderate or severe AKI within 12 hours of cardiac surgery. Clinical use of 
these markers has been marketed as Nephrocheck®. 
 
Recent studies reported the following:  
The combination of urinary TIMP-2 and IGFBP7 4 hours after postoperative ICU admission 
identifies patients at risk of developing AKI, not just stage 2–3 AKI, following cardiac 
surgery(16). 
Urinary [TIMP-2] × [IGFBP7] tests sufficiently detect patients with a risk of AKI after major 
high-risk surgery. Due to its rapid responsiveness, it extends the time frame for intervention to 
prevent the development of AKI(70). 
 
The findings indicate that urinary [TIMP-2] [IGFBP7] may be a reliable biomarker for the 
early detection of AKI. However, given the significant heterogeneity among the included 
studies, clinicians should be aware of the utility and limitations of this biomarker in clinical 
practice. Additional high-quality studies examining a larger sample of patients are required(71). 
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1.2 Background about aortic diseases and aortic surgery 
 
1.2.1 Anatomy of the Aorta (72) (Figure 3): 
The anatomy of the ascending aorta, aortic root, and aortic arch: 
The aortic root: is where the ascending aorta begins at the level of the aortic valve and the 
origins of the coronary arteries from the aortic root (sinuses of Valsalva)  
The ascending aorta: is anatomically defined as the part of the aorta between the aortic 
valve and the origin of the brachiocephalic trunk. 
The aortic arch: originates from the ascending aorta and continues as the descending 
aorta. It is anatomically defined as the part of the aorta between the brachiocephalic trunk 
until directly after the origin of the left subclavian artery, and gives rise to 3 main branches 
that supply the head, neck, and arms:  
 Brachiocephalic trunk 
 Left common carotid artery 
 Left subclavian artery 
 
The aortic arch continues as the descending aorta until the diaphragm then continues as the 
abdominal aorta until the 4th lumbar vertebrae, where the aorta is subdivided into right and left 
iliac arteries. The aortic root, ascending aorta, aortic arch and descending aorta together make 
up what is known as the thoracic aorta. 
 
                            Figure 3; Anatomy of the Aorta  
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NORMAL SIZES OF THE AORTA 
A healthy aorta is widest at the aortic root and narrows gradually until it divides into the 
pelvic arteries. Standard aortic diameter is <40mm. The aorta is typically larger in men than 
in women. The aorta transports about 200 million litres of blood over the course of an average 
lifespan and is continuously subjected to arterial blood pressure. To endure this constant 
strain, the aorta, like all organs, undergoes a continual adaptation and repair process. 
 
THE HISTOLOGICAL OVERVIEW OF THE AORTIC WALL (Figure 4): 
The aorta is an elastic artery formed of three layers. 
The innermost layer is the tunica intima, followed by the tunica media, with the outermost 
being the tunica adventitia.  
The intima is composed of the so-called endothelium, a single cohesive layer of flat cells. It 
controls, among other things, oxygen and gas exchanges between the blood and the vessel 
wall. Injury to the endothelium forms blood clots (thrombus). An embolism occurs when a 
thrombus is swept up into the bloodstream. 
The media consists primarily of ring-shaped smooth muscle cells. They regulate the vessel 
width and ensure a steady blood flow through their elasticity. 
The adventitia is a mesh of connective tissue fibres that anchor the vessel into its 
surroundings. The so-called "vasa vasorum" are tiny blood vessels that run through the 
adventitia to supply it with blood. 
 
Figure 4; The histological overview of the aortic wall 
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1.2.2 Diseases of the ascending aorta and aortic arch with the surgical 
indication for each of them(72) 
Aortic diseases can be divided into chronic aortic diseases and acute aortic syndromes. 
Chronic aortic diseases can trigger an acute event. Acute aortic syndromes typically lead to 
chronic aortic diseases. 
Table 4; An overview of aortic diseases and the possible underlying causes 
Chronic aortic diseases Acute aortic diseases Possible Causes 
 
• Aneurysm 
 
• Chronic dissection 
 
 
• Aortic rupture 
 Open rupture 
 Closed rupture 
• PAU (aortic ulcer) 
• Aortic dissection 
 Type A 
o with malperfusion 
o without malperfusion 
 Type B (only in descending or 
abdominal aorta, not in A. Ar. or 
as.A) 
o with malperfusion 
o without malperfusion 
 
• Atherosclerosis 
• Congenital connective tissue  
diseases (i.e. Marfan syndrome) 
• Inflammation of the aorta 
   – Infection 
   – Autoimmune diseases 
• Previous aortic dissection (chronic 
dissection) 
 
 
 
1.2.2.1  Aortic aneurysms  
An aortic aneurysm is the enlargement of the aorta to more than 1.5-times its standard size. 
As a general rule, this is a diameter of about 40 mm. 
 
Thoracic aortic aneurysm risk factors include: 
 Age. Thoracic aortic aneurysms occur most often in people aged 65 and older. 
 Tobacco use. Tobacco use is a strong risk factor for the development of an aortic 
aneurysm. 
 High blood pressure. Increased blood pressure damages the blood vessels in the 
body, raising the chance of developing an aneurysm. 
 The build-up of plaques in the arteries (atherosclerosis). The build-up of fat, 
calcification and other substances that can damage the lining of a blood vessel 
(atherosclerosis) increases your risk of an aneurysm. This is a more common risk in older 
people. 
 Family history. People who have a family history of aortic aneurysm are at increased 
risk of having one. People who have a family history of aneurysms tend to develop aneurysms 
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at a younger age and are at a higher risk of rupture. This is a primary risk factor for younger 
people. 
 Marfan syndrome and related disorders. People who have Marfan syndrome or 
related disorders such as Loeys-Dietz syndrome or Ehlers-Danlos syndrome have a 
significantly higher risk of thoracic aortic aneurysm. 
The clinical picture of ascending and aortic arch aneurysm:  
Very often, neither ascending nor aortic arch aneurysms cause any complications or 
symptoms until a certain size is reached; they are both often detected by chance during routine 
investigations like echocardiography (ultrasound of the heart) and chest x-ray.  
In the case of ascending aortic aneurysm, symptoms start to appear when the diameter of an 
aneurysm is so big that it causes dilatation of the aortic valve ring or the aortic root which 
leads to the symptoms of aortic valve insufficiency (e.g. reduced stamina, heart failure). 
Sometimes, those are the first symptoms for the patient. Other symptoms such as chronic 
persistent chest pain or upper body venous congestion can occur as a result of compression of 
the superior vena cava.  
In the case of aortic arch aneurysms, these very often remain asymptomatic until rupture. 
Compression of the trachea or the main bronchus can lead to stridor or dyspnoea, along with 
compression of the oesophagus, which leads to swallowing difficulties. Occasionally, with the 
continued expansion of an aneurysm, compression of the left recurrent laryngeal nerve may 
cause hoarseness of the patient’s voice.  
In general, an acute increase or severe persistent chest pain, "aortic pain", is a sign of a 
pending rupture (bursting) or dissection (tearing) of the aorta and requires emergency 
treatment. Some patients experience "aortic pain" connected to rapid enlargement of the 
aorta’s diameter. An unnoticed aortic aneurysm usually makes itself known through a sudden 
painful event. This event is known as acute aortic syndrome. 
Irrespective of the location of an aneurysm, 85% of patients have arterial hypertension. 
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Indications of surgical interference in ascending and aortic arch aneurysm: 
Aneurysms of the ascending aorta or the aortic root: 
(1) When the diameter of the ascending aorta aneurysm reaches 55 mm, surgery should be 
performed 
(2) If heart surgery is performed for any other reasons, the ascending aorta should be 
treated alongside if its diameter has reached 45 mm 
There are various diseases, which have a high risk of an aortic complication. In these cases, 
the aorta should be operated upon earlier.  
 patients with connective tissue diseases of the aorta, such as Marfan syndrome(17), 
without aortic valve replacement (AVR) => aortic diameter threshold diameter of 45 mm  
 with aortic valve replacement => aortic diameter threshold of 40 mm 
(3) Patients with bicuspid aortic valve(17) 
 without aortic valve replacement => aortic diameter threshold diameter of 50 mm  
 with aortic valve replacement => aortic diameter threshold of 45 mm 
(4) Patients with a strongly positive family history of dissection/rupture/sudden death 
should receive a surgical replacement of the ascending aorta as soon as the diameter reaches 
50mm.  
(5) For other particular risk factors such as rapid growth (growth rate ≥1 cm/year), leaking 
of the aortic valve or with a planned pregnancy, surgery should be performed when the aorta 
diameter reaches 45 mm.  
(6) Symptomatic patients should undergo aneurysm resection, regardless of aneurysm 
size. Acutely symptomatic patients require an emergency operation. 
 
Aneurysm of the aortic arch 
(1) When the diameter of the aorta arch aneurysm reaches 55 mm, surgery should be 
performed 
(2)  If an operation on a bordering section of the aorta is planned, the aortic arch can 
sometimes also be replaced, even if the diameter is smaller than 55mm 
(3) Symptomatic patients should undergo aneurysm resection, regardless of aneurysm 
size. 
 
1.2.2.2  Aortic dissection 
An aortic dissection occurs in a weakened area of the aortic wall as cleavage in the aortic 
wall’s three layers. In contrast to an aortic rupture, blood does not flow out of the aortic wall 
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but instead accumulates between the aortic wall layers, lifting the innermost layer, the intima, 
away from the aortic wall. 
As the dissection advances, a new channel for blood flow is created. This is called a "false 
lumen". The original vascular channel is called the "true lumen". The "false lumen" usually 
develops in the direction of the blood flow.  
Causes: 
(1) Aortic aneurysm 
(2) Chronic high blood pressure may stress the aortic tissue, making it more susceptible 
to tearing.  
(3) Congenital conditions associated with a weakened and enlarged aorta, such as Marfan 
syndrome  
(4) Bicuspid aortic valve or other rarer conditions related to the weakening of the walls 
of the blood vessels.  
(5) Rarely, aortic dissections are caused by traumatic injury to the chest area, such as 
during motor vehicle accidents. 
Aortic dissections are divided into two groups according to the Stanford Classification, 
depending on which part of the aorta is affected: 
 Type A. Mainly affects the ascending aorta, which may extend more distally to affect 
other parts of the aorta, including the “arch, descending aorta, the abdominal aorta or even the 
pelvic and groin vessels”. 
This is the more common (about more than 65% of aortic dissections) and more dangerous 
type; its risk arises from the possible involvement of the aortic valve, coronary vessels and 
vessels to the head which can cause sudden death through rupture and bleeding into the 
pericardium (pericardial tamponade) with subsequent heart failure and heart arrest. As a 
result of the potential for complications, an untreated "Type A dissection" has a high mortality 
rate of about 40–60% in the first 48 hours (around 1% per hour). 
 Type B. This involves a tear in the lower aorta only (descending aorta), which may 
also extend into the abdomen. 
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Risk factors for aortic dissection include: 
 Uncontrolled high blood pressure (hypertension) 
 Hardening of the arteries (atherosclerosis) 
 Weakened and bulging artery (pre-existing aortic aneurysm) 
 An aortic valve defect (bicuspid aortic valve) 
 A narrowing of the aorta at birth (aortic coarctation) 
Certain genetic diseases increase the risk of having an aortic dissection, including: 
 Turner's syndrome. High blood pressure, heart problems and some other health 
conditions may result from this disorder. 
 Marfan syndrome. This is a condition in which connective tissue, which supports 
various structures in the body, is weak. People with this disorder often have a family history 
of aneurysms of the aorta and other blood vessels or family history of aortic dissections. 
 Other connective tissue disorders. This includes Ehlers-Danlos syndrome, a group 
of connective tissue disorders characterised by skin that bruises or tears easily, loose joints 
and fragile blood vessels and Loeys-Dietz syndrome, with twisted arteries, especially in the 
neck. 
 Inflammatory or infectious conditions. These may include giant cell arteritis, which 
is an inflammation of the arteries, and syphilis, a sexually transmitted infection. 
 
Clinical picture 
An acute aortic dissection is expressed in a sudden event of characteristically sudden 
(impending death) chest pain; as the dissection progresses distally, the pain location also 
migrates from the anterior chest to the throat, neck and subsequently between the scapulae. 
Aortic dissection can block the vessels originating from the aorta, causing a heart attack, 
stroke, paraplegia, acute malperfusion syndrome (disturbance in the blood supply) of the arms 
or legs, or insufficient blood supply to the abdominal organs. 
A sudden discrepancy in the blood pressure of the extremities in association with painful 
event points towards an aortic dissection. After an aortic dissection, the blood is contained 
only by the thin outer wall layer (adventitia). A complete aortic rupture becomes a possible 
complication.  
A well-known history of hypertension, a well-known thoracic aortic aneurysm, or a diagnosis 
of Marfan syndrome should always be an alarm signal for a dissection. 
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Indication for surgery 
Immediately on suspicion of an aortic dissection, aggressive drug therapy should be started 
immediately with the goal of setting pain control and blood pressure reduction. Preferably, 
intravenous beta-blockers are used, since they reduce aortic wall stress and thus reduce the 
possibility of rupture. 
(1) Acute type A dissection and intramural haematoma of the ascending aorta should be 
considered surgical emergencies.  
(2) All clinical symptoms of malperfusion of the myocardium, brain, spinal cord, visceral 
organs, and extremities are considered indicative of an emergency procedure.  
(3) The aortic arch then has to be additionally surgically treated when intimal dissections 
are arched or when the dissection is on the floor of a pre-existing fusiform aneurysm. 
(4) In cases of chronic dissection in the ascending aorta, immediate intervention for 
rupture and severe aortic valve regurgitation is indicated.  
(5) Usually, patients with chronic type A dissection have a stable condition with a dilated 
ascending aorta and mild to severe aortic insufficiency. The risk of a rupture always exists, 
and the elective replacement of the aorta is indicated by a diameter of >5 cm. On the other 
hand, in patients with Marfan syndrome, elective replacement with a diameter of >4 cm 
should be considered. 
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1.3 Aims and Objective 
 
The overall objective of this study was to evaluate the incidence surrounding acute renal 
failure after ascending and aortic arch replacement surgery that required moderate 
hypothermic circulatory arrest and cardiopulmonary bypass.  
 
More specifically, we wanted to: 
1.3.1 To determine the predictors of PCS-AKI from the different surgical techniques used in 
ascending aorta replacement vascular surgery as hypothermic circulatory arrest time (HCAT), 
CPB time and blood transfusion. 
1.3.2 Investigate the incidence of AKI after ascending aorta and aortic arch replacement 
surgery with moderate HCA and CPB. 
1.3.3 Evaluate the outcome of PCS-AKI by measuring the mortality and morbidity rate of 
the critically ill patients who underwent those surgeries 
1.3.4 Evaluate the known renal replacement therapy prediction scores of the PCS and the 
other risk and predisposing factors of PCS-AKI not mentioned in those prediction scores. We 
measured those variant parameters and the risk factors involved in those prediction scores and 
correlated them with serial perioperative kidney function measurements by using the correct 
statistical evaluation for them. This will subsequently lead us to decrease the postoperative 
AKI by avoiding those risk factors; and when avoidance is not available, then by early 
therapeutic intervention. 
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2. Materials and Methods 
 
2.1  Literature 
Before starting the analyses, the previous literature was studied. Articles were found using 
PubMed and the following keywords in the different search engines: postoperative acute 
kidney injury, post-cardiac surgery AKI, hypothermic circulatory arrest, cardiopulmonary 
bypass, RIFLE, AKIN, KDIGO and ascending aorta replacement surgery.  
References in the identified articles were also used. These articles were used in the 
introduction and discussion section of this thesis. An overview of the articles can be found 
under references. The references were compiled using “Endnote”. 
 
2.2  Study population & design  
General-patient population 
In the presented retrospective cohort study, the database for Kiel University clinic was 
searched for patients with aortic arch and aortic ascending replacement surgeries with HCA 
and CPB techniques. Between January 1, 2001, and December 31, 2017. 1359 patients were 
found in our database with different causes for those operations such as ascending aortic and 
aortic arch -aneurysm, -dissections or -calcifications, who were operated upon. The patient 
records were abstracted, and the data were entered into a database and then revised for 
accuracy by randomly checking chart data with data on the computer.  
Preoperative coexisting medical problems and variables, as well as operative technique 
variables and postoperative and follow-up complications, were recorded; all preoperative, 
operative and postoperative variables and data are presented in tables 5,6,7 and 8 in the result 
section. 
Acute renal failure was measured based on the KDIGO criteria (Figure 1). 
 
2.3 Inclusive and Exclusive Criteria 
Inclusion criteria were that the patient underwent an ascending aorta replacement surgery, an 
aortic arch replacement surgery or both together, regardless of other additional operations 
performed simultaneously, with a minimum age of 18 years.  
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No general exclusion criterion existed, except for missing data.  
 
2.4 Clinical Data collection and Ethical considerations 
 
The basis of the analysis was the patient records of uni-clinic Kiel. These include the 
corresponding preclinical emergency physician protocol including the patient's first contact 
and any resuscitation protocol before arriving at the hospital as well as all the in-patient 
documentation in the clinic database. 
The entry was made retrospectively by accessing the patients’ archived files in the hospital's 
electronic database. For this purpose, pre-clinic emergency physician protocols, medical 
history sheets, operative and anaesthesia protocols and follow-up documentation in intensive 
care and intermediate care units, as well as normal station, serial laboratory and blood gas 
analysis results during the hospital stay, consultation findings, and medical reports were used 
and evaluated. 
Seven-day and thirty-day mortality-rate follow-up was performed for all patients. House 
doctors (Hausärzte) were called for all patients who were released from the hospital before 30 
days of their operation date, to ask whether they were still alive or not; in cases of death 
within the first 30 postoperative days after release from the hospital, the time and cause of 
death was recorded. 
The patient data collected were subdivided into three main categories, pre-, intra- and post-
operative (as mentioned before) using Microsoft Excel®, and included all study-related 
information. The patient registration and evaluation took place exclusively in the 
pseudonymised form using a sequential number. The collected data remained in a computer 
file in the hospital where it was only possible for the project team to access.  
This retrospective study was conducted by and after receiving the positive opinion of the 
Ethics Committee of Kiel University as well as the hospital’s Leaders. 
 
2.5  Statistical analysis 
All Statistical analyses were performed by ANALYSE-IT®, which is a statistical analysis 
add-on for Microsoft Excel. Analyse-it is the successor to Astute, developed in 1992 for Excel 
4, and the first statistical analysis add-on for Microsoft Excel. The data collection took place 
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with Microsoft Excel, and the quantitative variables values are presented as the mean ±  
Standard deviation. 
 Paired t-test 
The paired t-test was used to compare related values (values for each patient were paired together) 
with each other. A probability level (p-value) of less than 0.05 has been considered to indicate 
statistical significance. 
 
 Spearman’s correlations coefficient 
The correlation coefficient (Spearman’s rank correlation) should generally be at least 0.3 to 
show a relationship; values up to 0.2 are considered as "very low correlation", values up to 
0.5 as "low correlation", values up to 0.7 as "medium", up to 0.9 as "high" and >0.9 as "very 
high correlation"; this also applies to negative correlations. 
 
2.6 Operation technique(72) 
Short introduction 
Medial sternotomy provides access to the ascending aorta or aortic arch 
The surgical repair of an aneurysm and dissection of the aorta involves replacing the affected 
aortic segment with a vascular prosthesis, usually associated with an aortic valve replacement. 
The procedure is performed using the heart-lung machine and systemic hypothermia (24-
28°C).  
Operations on the aortic arch require the use of deeper hypothermic cardiac arrest (18-24°C) 
primarily to protect the brain. As additional protective measures, both antegrade (directly via 
right and left internal carotid artery) and retrograde perfusion (indirectly via superior vena 
cava) may be used. 
 
2.6.1 Technical requirements for surgery 
 
Circulatory arrest 
Because of the location of the aortic arch and the vessels that originate here, it cannot be 
cross-clamped for replacement. For operations of the aortic arch, the heart-lung machine must 
be turned off for a short amount of time. Circulatory arrest then ensues. After removing the 
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aneurysms and suturing in the vascular prosthesis, circulation is again started via the heart-
lung machine.  
To avoid damage to the organs due to a lack of oxygen, various techniques are used to protect 
the organs (see the following techniques). 
 
Hypothermia 
Lowering the body temperature (hypothermia) reduces the cellular need for energy and, as 
a result, for oxygen. Cooling the body can, therefore, be used as a technique to protect organs 
from a lack of oxygen. This has been used since the 1960s in interventions in the aorta, in 
particular, to protect the brain (so-called neuroprotection), the least tolerant organ for 
oxygen shortage. 
Cooling the entire body to temperatures less than 20°C is achieved indirectly with the heart-
lung machine, which cools the circulating blood. After completing the aortic replacement 
under circulatory arrest and hypothermia, the body is again warmed with the heart-lung 
machine. 
 
Cardiopulmonary bypass through the Heart-lung machine 
Operations on the ascending aorta and aortic arch are carried out with a heart-lung machine 
which takes over the patient’s blood circulation and the supply of oxygen. It is connected to 
the heart’s right atrium and the aorta. Blood flows into the heart-lung machine, where it is 
enriched with oxygen, cooled or warmed and pumped back into the patient’s aorta. The lungs 
and heart are thereby circumvented. In this way, operations on "open", non-beating hearts 
can be carried out.  
The blood is thinned with the help of heparin so that it does not clot in the tubes of the heart-
lung machine. In aortic surgery using a heart-lung machine, the surgeon tries to seal off the 
segment being replaced with clamps (cross-clamping). After suturing in a vascular prosthesis, 
the blood flow is again released into the treated segment. 
 
Selective antegrade or retrograde cerebral perfusion 
To support neuroprotection, the technique of selective antegrade cerebral perfusion was 
developed.  
This means that only the brain vessels (directly via only right and left internal carotid artery 
(=selective) in the normal direction of the blood flow (=antegrade) are supplied (=perfusion) 
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with blood from the heart-lung machine during circulatory arrest, and retrograde perfusion 
(indirectly via superior vena cava) may be used. 
In this way, a continual influx of nutrients and oxygen is maintained and an extension of the 
period of "safe circulatory arrest" is achieved. Because the abdominal organs react with less 
sensitivity than the brain to circulatory arrest, the lower body temperature under circulatory 
arrest can be raised (25-28°C) when cerebral perfusion is used. 
 
Aortic prostheses 
Aortic prostheses are made out of polyester. This is a high-quality synthetic fibre that is 
woven into tubular-shaped vascular prostheses. The prosthesis is designed with small pleats to 
provide flexibility to fit the patient’s anatomy. Because the woven material is not leak proof, 
it is sealed with collagen or gelatine.  
There are many sizes and variations of aortic prostheses. The simplest prostheses are straight 
grafts. Complex prostheses have side branches for attaching vessels, a portal for the heart-
lung machine or a section with a stent graft (so-called hybrid prostheses). 
The surgical team in Hanover, Germany, in collaboration with Vascutek, a producer of 
medical devices, has already developed an aortic prosthesis with all of these characteristics 
(Thoraflex Hybrid prosthesis, see aortic arch replacement). 
Composite aortic prostheses are still produced by hand. Sometimes, several thousand stitches 
are necessary to suture an aortic prosthesis together. Production can take up to eight weeks. 
 
2.6.2 Different Operations Types(72) 
 
Aortic valve reconstruction “aortic root reconstruction” 
By the end of the 1950s, techniques to reconstruct the aortic valve were already in use. The 
advantage over valve replacement using mechanical valves lies in the lack of a need for a 
long-term blood thinner (e.g. with warfarin) and the reduced vulnerability of valve infection. 
An aortic valve reconstruction is only possible when the valve cusps show no severe 
structural changes (e.g. calcification).  
Aortic valve reconstruction is suited to treating enlargements of the aortic root that are 
associated with leaking of the aortic valve. The most commonly applied technique for aortic 
valve reconstruction is the so-called David procedure or aortic valve re-implantation. It was 
first introduced in 1992 by Prof Tirone David.  
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The entire ascending aorta is removed, apart from a small rim above the aortic valve. The 
coronary arteries are detached from the aorta as so-called buttons. Below the aortic valve, 
stabilising sutures are subsequently sewn through the aortic wall from inside to outside. With 
these sutures, an aortic prosthesis is pulled down over the outside of the aortic valve and 
secured deep into the aortic root. The aortic valve is now sutured into the aortic prosthesis. 
Finally, the two coronary arteries are reimplanted. 
For several decades various techniques for aortic valve reconstruction have been employed. In 
1982, a technique was described by Sir Magdy Yacoub in which the ascending aorta is 
removed to just above the aortic valve and replaced with an aortic prosthesis that is cut to the 
appropriate size. 
This so-called aortic valve remodelling technique does not involve a root stabilisation 
procedure. To prevent a later enlargement in the root, this technique can be combined with 
various stabilising techniques. 
 
Aortic valve replacement 
Aortic valve replacement is necessary when structural changes in the valve (mostly 
calcification) lead to a severe narrowing (stenosis) or leaking (insufficiency) of the aortic 
valve. In many aortic operations of the ascending aorta, the aortic valve is also affected and 
must be replaced when it cannot be reconstructed. 
The original, no longer functional heart valve is cut out of the aortic valve annulus (a fibrous 
ring). The calcified materials in the aortic valve annulus are removed with special forceps. 
The annulus is then measured, and an appropriate prosthetic valve is chosen. Following this, 
sutures are placed in the aortic valve annulus. These threads are then sewn through the sewing 
ring of the prosthetic valve. The prosthetic valve is guided down into the annulus. The sutures 
are tied off, and the prosthetic valve is checked for correct positioning. 
 
Mechanical prostheses 
Mechanical valves are heart valve prostheses made out of synthetic materials. Most consist of 
a valve annulus in which two leaflets or cusps are attached to the inside. On the outside, a 
sewing ring is affixed.  
Mechanical valve prostheses have the advantage of being virtually unlimited durability. The 
disadvantage of this prosthesis is that the foreign surface of the prosthetic valve activates 
blood clotting. This drives clot formation on the prosthetic valve when coagulation is not 
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inhibited. This also leads to a risk of stroke. Therefore, patients who have a mechanical heart 
valve must take blood-thinning medication for the rest of their lives.  
Most commonly, warfarin is given. A side effect is that warfarin can cause unwanted bleeding 
(e.g. gastrointestinal haemorrhage). Therapy requires the regular measurement of clotting 
parameters. This happens at intervals of several weeks by a general practitioner or can be 
performed by the patient with a measurement device. 
 
Bio-prostheses 
Biological prosthetic valves consist mostly of bovine pericardial tissue or porcine heart valves 
that are fixed to a sewing ring. 
The main advantage of these prostheses is that they do not activate blood clotting, so the 
patient only needs to follow a blood-thinning therapy for a short time after surgery (about 2-3 
months). 
The disadvantage of bioprostheses is that they calcify and degenerate over time. In this way, a 
new narrowing of the valve or leaking can develop. The valve must be replaced again. The 
lifespan of biological prosthetic valves is 12-15 years on average. 
 
Replacement of the ascending aorta with aortic root “conduit, Bentall-operation-valved 
conduit”(72) 
If the aortic valve, aortic root, and ascending aorta all need to be replaced at once, composite 
grafts that consist of an aortic prosthesis and a prosthetic aortic valve are used. 
So-called valved conduits are either sewn together at the factory or constructed by the surgeon 
during the operation. 
 
Supra-coronary replacement of the ascending aorta  
If only the ascending part of the supra-coronary aorta is affected by an aneurysm or 
dissection, this can be replaced as a rule with a simple, straight aortic prosthesis (so-called 
"tube graft"). 
For this, the ascending aorta is clamped - if possible - before the aortic arch, and during a 
short period of cardiac arrest, the aorta is wholly excised, both proximally just above the 
opening of the coronary arteries, and distally. A Dacron tube prosthesis of appropriate size is 
then anastomosed, first distally with the aorta, and finally by proximal anastomosis. The heart 
is again perfused with blood and begins to beat. 
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Partial aortic arch replacement 
For many patients who undergo surgery due to an aneurysm of the ascending aorta, a small 
part of the aortic arch is also replaced under a short period of circulatory arrest. The 
replacement of the entire aortic arch is not necessary. It is often called "hemi-arch 
replacement", "partial aortic arch replacement" or more accurately "open anastomosis", 
because the aortic arch must be briefly opened, without it being completely replaced, for the 
suturing in of the ascending aortic prosthetic. 
For a short period of circulatory arrest, patients must be cooled (24-28°C) to protect the 
organs. Also, the vessels to the head are sometimes supplied with blood via a special catheter 
(antegrade cerebral perfusion), in particular when the suturing of the aortic prosthesis is 
expected to take longer than ten minutes. 
 
Total aortic arch replacement 
Because of the anatomical characteristics, replacing the entire aortic arch is one of the most 
complex interventions in heart surgery. 
The three arteries that supply the arms and head with blood begin at the aortic arch. After the 
aortic arch, the aorta transitions into the descending aorta, which supplies the lower part of the 
body with blood. The aortic arch can only be opened when the blood flow to these arteries is 
temporarily stopped. Thus, the operation takes place under circulatory arrest. 
After opening the aortic arch during circulatory arrest (18-24°C), each vessel to the head is 
perfused (so-called selective antegrade cerebral perfusion) with a special catheter to supply 
the brain with oxygen. Initially, the lower part of the body remains in circulatory arrest. At a 
later point, it will again be supplied with blood via a prosthetic aortic arch. The circulatory 
arrest then ends.  
The arteries that begin at the aortic arch are sewn into the aortic prosthesis either grouped as a 
combined "island" or separately. 
There are special prostheses with four side arms (three for connecting the vessels and one for 
the heart-lung machine) available for the latter technique. It is casually called the "four finger 
prosthesis". In order to better suture it into the distal aortic arch (section of the aortic arch 
closest to the descending aorta), it has a "collar". 
If the enlargement extends to the descending part of the aorta, this must usually be treated in a 
later, second operation via the left side of the chest. This can be facilitated by leaving a part of 
the prosthetic aortic arch "dangling" freely in the bloodstream in the first operation, which 
will serve as a starting point for the second operation. This technique is called the "elephant 
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trunk" technique. It was developed in Hanover, Germany by Professor Hans-Georg Borst 
and first introduced in 1983.  
If the elephant trunk part of the prosthetic aortic arch is also equipped with a stent graft, it is 
called the "frozen elephant trunk" technique because the prosthesis no longer "dangles" 
freely but is fixed or "frozen". Because these prostheses are part "normal" aortic prosthesis 
and part "stented", they are called hybrid prostheses. 
If only the beginning of the descending aorta is affected in addition to the aortic arch, a 
second operation can be skipped by using such hybrid prostheses. The first "frozen elephant 
trunk" prosthesis was developed in Hanover, Germany (Haverich-Chavan prosthesis) and has 
been continually improved since then. The Thoraflex™ Hybrid prosthesis by Vascutek now 
exists, which is an aortic arch prosthesis that combines all of the features mentioned above. It 
is, at the moment, the most complex aortic prosthesis available. 
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3. Results 
3.1   General data: 
 
Demographic and clinical characteristics of the study population (Table 5):  
Preoperative coexisting medical problems and variables include sex, age, preoperative 
comorbidities and cardiopulmonary status. 
The mean age of the patients was 66.7±11 years (range 16–88 years). Of these, 903 (66.5%) 
were male, and 465 (33.5%) were female. Solo acute aneurysm was present in 890 (65.4%) 
patients, while solo dissection was present in 256 (18.8%), combined acute aneurysm and 
dissection was present in 117 (8.6%) patients, and calcification in 143 (10.5%); some were 
overlapping with aneurysm and dissection. 
The results are summarised in table 5. 
Table 5; Preoperative variables and data 
 Total Male Female P-
value 
No. of patients  1359 (100%) 903 (66.5%) 464 (33.3%) ---- 
Age, years 66.7±11.1 
69.2 (61.0;74.4) 
65.8±11.6 
68.3 (58.9;74.1) 
68.4±9.9 
70.2 
(64.0;75.6) 
0.002 
Logistic EuroSCORE (%) 14.4 (9.0;25.1) 12.3 (7.4;22.6) 18.4 
(11.7;29.2) 
<0.001 
EuroSCORE II (%) 4.12 (2.38;7.13) 3.7 (2.2;6.6) 4.7 (2.8;7.5) 0.001 
EuroSCORE (%) 9.0 (7.0;11.0) 8 (7;10) 10 (8;11) <0.001 
Body mass index, kg/m2 26.5 (24.2;29.4) 26.8 (24.5;29.4) 25.7(23.0;29.1
) 
0.001 
Arterial hypertension 687 (75.9%) 442 (73.2%) 245 (81.4%) 0.006 
Pulmonary hypertension 55 (6.1%) 38 (6.3%) 17 (5.6%) 0.703 
Type 1 Diabetes mellitus  1 (0.1%) 0 (0.0%) 1 (0.3%) 0.333 
Type 2 Diabetes mellitus 108 (11.9%) 71 (11.7%) 37 (12.2%) 0.732 
      Oral medication 70 (7.7%) 47 (7.8%) 23 (7.6%) ---- 
      Insulin dependent 28 (3.1%) 19 (3.1%) 9 (3.0%) ---- 
      Dietary treatment 10 (1.1%) 5 (0.8%) 5 (1.7%) ---- 
Diabetic nephropathy 0 (0.0%) 0 (0.0%) 0 (0.0%) ---- 
Diabetic neuropathy 3 (0.3%) 3 (0.5%) 0 (0.0%) 0.555 
Hyperlipoproteinaemia 367 (40.6%) 253 (41.9%) 114 (38.0%) 0.262 
Chronic renal failure 99 (11.0%) 77 (12.8%) 22 (7.3%) 0.013 
Decompensated renal insufficiency 13 (1.4%) 8 (1.3%) 5 (1.7%) 0.769 
Renal replacement therapy 10 (1.1%) 8 (1.3%) 2 (0.7%) 0.510 
COPD 104 (11.5%) 64 (10.6%) 40 (13.3%) 0.235 
Smoking 176 (19.8%) 118 (19.7%) 58 (19.9%) 0.944 
Previous smoking 270 (30.5%) 196 (32.9%) 74 (25.4%) 0.023 
Coronary heart disease 350 (38.8%) 258 (42.9%) 92 (30.6%) <0.001 
     One-vessel disease 175 (19.4%) 116 (19.3) 59 (19.6%) ---- 
     Two-vessel disease 63 (7.0%) 46 (7.7%) 17 (5.6%) ---- 
     Three-vessel disease 112 (12.4%) 96 (16.0%) 16 (5.3%) ---- 
Heart rhythm     
     Sinus rhythm 707 (78.1%) 471 (78.0%) 236 (78.4%) 0.884 
     Atrial fibrillation 163 (18.0%) 110 (18.2%) 53 (17.6%) 0.824 
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     Other 74 (8.2%) 50 (8.3%) 24 (8.0%) 0.869 
Pacemaker patient 32 (3.5%) 20 (3.3%) 12 (4.0%) 0.604 
Defi patient 5 (0.6%) 3 (0.5%) 2 (0.7%) 0.669 
Previous PCI (+/-DES) 84 (9.3%) 66 (10.9%) 18 (6.0%) 0.016 
Previous thoracic surgery 100 (11.0%) 70 (11.6%) 30 (10.0%) 0.463 
Previous CABG 23 (2.5%) 19 (3.2%) 4 (1.3%) 0.101 
Peripheral vascular disease 51 (5.6%) 34 (5.6%) 17 (5.6%) 0.991 
LVEF (%) 64 (53;70) 62 (51;70) 65 (55;70) 0.010 
LVEF     0.118 
     Good (≥55%) 634 (74.2%) 408 (72.0%) 226 (78.7%) ---- 
     Slightly impaired (45-54%) 115 (13.5%) 81 (14.3%) 34 (11.8%) ---- 
     Moderately impaired (30-44%) 82 (9.6%) 59 (10.4%) 23 (8.0%) ---- 
     Severely impaired (<30%) 23 (2.7%) 19 (3.4%) 4 (1.4%) ---- 
Diagnostic imaging     
     Computed tomography 506 (56.0%) 326 (54.1%) 180 (59.8%) 0.101 
     Coronary angiography 861 (95.1%) 578 (95.7%) 283 (94.0%) 0.270 
     Magnetic resonance imaging 33 (3.6%) 22 (3.6%) 11 (3.7%) 0.993 
Marfan syndrome 9 (1.0%) 7 (1.2%) 2 (0.7%) 0.726 
Aortic aneurysm 823 (90.9%) 552 (91.4%) 271 (90.0%) 0.503 
Diameter of aneurysm, mm 52 (50;57) 52 (50;55) 53 (50;60) 0.004 
Calcific aortic disease 113 (12.5%) 74 (12.3%) 39 (13.0%) 0.762 
Bicuspid aortic valve 104 (23.5%) 85 (28.1%) 19 (13.5%) 0.001 
Aortic valve vitium    0.042 
     Aortic valve stenosis 145 (16.9%) 108 (19.0%) 37 (12.8%) ---- 
     Aortic valve insufficiency 329 (38.3%) 203 (35.7%) 126 (43.6%) ---- 
Neurological deficits 123 (13.6%) 73 (12.1%) 50 (16.6%) 0.063 
Clinical presentation     
     Acute myocardial  infarction (48h) 10 (1.1%) 8 (1.3%) 2 (0.7%) 0.510 
     Cardiogenic shock 5 (0.6%) 5 (0.8%) 0 (0.0%) 0.176 
     CPR 6 (0.7%) 5 (0.8%) 1 (0.3%) 0.670 
Intubated 7 (0.8%) 2 (0.3%) 5 (1.7%) 0.044 
Urgency of admission    0.095 
     Elective 821 (90.9%) 553 (91.9%) 268 (89.0%) ---- 
     Urgent 62 (6.9%) 34 (5.6%) 28 (9.3%) ---- 
     Emergency 20 (2.2%) 15 (2.5%) 5 (1.7%) ---- 
Preoperative status     
    Stable 892 (98.6%) 596 (98.7%) 296 (98.3%) ---- 
    Stable with low dose catecholamine 11 (1.2%) 6 (1.0%) 5 (1.7%) ---- 
    Stable with high dose catecholamine  2 (0.2%) 2 (0.3%) 0 (0.0%) ---- 
 
Preoperative medication (Table 6): 
The preoperative cardiovascular medicines that were used by each of the patients before the 
surgery. The most three used drugs were beta-blocker, ACEI and acetylsalicylic acid with a 
percentage of 56.2%, 44.2% and 39.3%, respectively.   
The results are summarised in table 6. 
Table 6; Preoperative medication 
 Total Male Female P-
value 
ACE inhibitor 376 (44.2%) 264 (46.2%) 112 (40.1%) 0.097 
AT1-receptor antagonist 159 (18.7%) 101 (17.7%) 58 (20.8%) 0.271 
Aldosterone antagonist 16 (1.9%) 9 (1.6%) 7 (2.5%) 0.346 
Acetylsalicylic acid 335 (39.3%) 243 (42.4%) 92 (32.9%) 0.007 
Clopidogrel 55 (6.4%) 41 (7.2%) 14 (5.0%) 0.229 
Ticagrelor 3 (0.4%) 3 (0.5%) 0 (0.0%) 0.555 
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Prasugrel 3 (0.4%) 1 (0.2%) 2 (0.7%) 0.252 
Marcumar 88 (10.3%) 63 (11.0%) 25 (8.9%) 0.347 
Beta-Blocker 479 (56.2%) 315 (55.1%) 164 (58.6%) 0.333 
Statin 299 (35.3%) 211 (37.2%) 88 (31.5%) 0.105 
NSAIDs 28 (3.5%) 18 (3.4%) 10 (3.8%) 0.786 
 
Operative data (Table 7): 
Intraoperative variables included operation urgency and time, hypothermic circulatory arrest 
time (HCAT), cardiopulmonary bypass (CPB) time, aortic cross-clamp time, blood 
transfusion and surgery type and procedure. 
The results are summarised in table 7 
Table 7; Intraoperative data 
 Total Male Female P-
value 
Urgency     
     Elective 809 (89.5%) 550 (91.1%) 259 (86.3%) ---- 
     Urgent 75 (8.3%) 43 (7.1%) 32 (10.7%) ---- 
     Emergency 19 (2.1%) 10 (1.7%) 9 (3.0%) ---- 
Length of surgery, min 250 (203;308) 260 (210;320) 225 (195;285) <0.001 
Cardiopulmonary bypass time, min 142 (113;187) 150 (118;192) 132 (105;175) <0.001 
Cross-clamp time, min 92 (65;125) 97 (73; 129) 83 (56;110) <0.001 
Circulatory arrest time, min 14 (12;18) 14 (12;17) 15 (13;19) 0.003 
Number of packed red blood cells 2 (0;4) 2 (0;3) 2.5 (2;4) <0.001 
Number of fresh frozen plasma 0 (0;0), max 18 0 (0;0), max 18 0 (0;3) 0.115 
Number of platelet concentrate 1 (0;1) 1 (0;2) 1 (0;1) 0.871 
Surgical procedure     
     Ascending aorta 757 (83.6%) 488 (80.8%) 269 (89.4%) 0.001 
Diameter of ascending aorta prostheses 30 (28;32) mm 30 (28;32) mm 30 (28;32) mm 0.075 
     Partial arch replacement 203 (22.4%) 137 (22.7%) 66 (21.9%) 0.797 
     Total arch replacement 29 (3.2%) 19 (3.1%) 10 (3.3%) 0.880 
     Conduit/Bentall Operation 149 (16.5%) 113 (18.7%) 36 (12.0%) 0.010 
     David operation 63 (7.0%) 38 (6.3%) 25 (8.3%) 0.262 
     Elephant-trunk 9 (1.0%) 6 (1.0%) 3 (1.0%) 1.000 
     CABG 222 (24.6%) 174 (28.8%) 48 (16.0%) <0.001 
     Aortic valve replacement 462 (51.0%) 325 (53.8%) 137 (45.5%) 0.019 
Number of distal anastomosis 0 (0;1) 0 (0;2) 0 (0;1) <0.001 
Number of arterial grafts  0 (0;1) 0 (0;1) 0 (0;0) <0.001 
Mitral valve reconstruction /replacement 27 (3.0%) 17 (2.8%) 10 (3.3%) 0.672 
Tricuspid valve reconstruction / 
replacement 
1 (0.1%) 1 (0.2%) 0 (0.0%) 1.000 
PFO-closure 46 (5.1%) 38 (6.3%) 8 (2.7%) 0.019 
MAZE procedure 26 (2.9%) 18 (3.0%) 8 (2.7%) 0.784 
Carotid 10 (1.1%) 8 (1.3%) 2 (0.7%) 0.510 
TEVAR(EVAR) 2 (0.2%) 0 (0.0%) 2 (0.7%) 0.110 
Arterial cannulation     
     Femoral artery 10 (1.2%) 9 (1.6%) 1 (0.4%) ---- 
     Ascending aorta 680 (80.2%) 455 (80.4%) 224 (79.7%) ---- 
     Aortic arch 107 (12.6%) 71 (12.5%) 36 (12.8%) ---- 
     Apex 2 (0.2%) 2 (0.4%) 0 (0.0%) ---- 
     Pulmonary vein 48 (5.7%) 28 (4.9%) 20 (7.1%) ---- 
Venous cannulation     
     Right atrium 786 (92.8%) 520 (91.7%) 266 (95.0%) ---- 
     Bicaval 55 (6.5%) 42 (7.4%) 13 (4.6%) ---- 
     Femoral vein 5 (0.6%) 4 (0.7%) 1 (0.4%) ---- 
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Postoperative data and outcomes (Table 8): 
Postoperative variables including all possible complication, ICU time, Seven-day and thirty-
day mortality-rate follow-up was performed for all patients as well as the cause of death for 
each of them. 
The results are summarised in table 8. 
Table 8; postoperative variables and data 
 Total Male Female P-
value 
AKI KDIGO 48 (5.3%) 30 (5.0%) 18 (6.0%) 0.518 
AKI KDIGO stages     
1 1 (2.1%) 0 (0.0%) 1 (5.6%) ---- 
2 0 (0.0%) 0 (0.0%) 0 (0.0%) ---- 
3 47 (97.9%) 30 (100.0%) 17 (94.4%) ---- 
New –onset of Hemodialysis 48 (5.3%) 30 (5.0%) 18 (6.0%) 0.518 
Temporary dialysis, d  5.0 (2.0;15.0) 5.0 (1.8;14.5) 5.0 (2;16) 0.686 
48 h-drainage loss, ml 600 (400;950) 600 (400;950) 550 
(330;1000) 
0.011 
24 h-Number of packed red blood cells,  0 (0;2) 0 (0;2) 0 (0;2) 0.409 
24 h-Number of fresh frozen plasma 0 (0;1) 0 (0;1) 0 (0;2) 0.595 
24 h-Number of platelet concentrate 0 (0;0), max 16 0 (0;0), max. 16 0 (0;0), max 9 0.766 
Total number of packed red blood cells,  1 (0;2) 0 (0;2) 1 (0;3) 0.148 
Total number  of fresh frozen plasma 0 (0;2) 0 (0;2) 0 (0;2) 0.581 
Total number  of platelet concentrate 0 (0;0), max. 18 0 (0;0), max. 16 0(0;0),max. 18 0.240 
Postoperative status     
     Stable 325 (36.0%) 221 (36.7%) 104 (34.8%) ---- 
     Stable with low dose catecholamine 533 (59.1%) 353 (58.5%) 180 (60.2%) ---- 
     Stable with high dose catecholamine 33 (3.7%) 23 (3.8%) 10 (3.3%) ---- 
     IABP/ECLS 10 (1.1%) 6 (1.0%) 4 (1.3%) ---- 
Reintubation 76 (8.4%) 54 (9.0%) 22 (7.3%) 0.408 
Tracheotomy 69 (7.6%) 50 (8.3%) 19 (6.3%) 0.300 
Re-admission to the ICU 53 (5.9%) 33 (5.5%) 20 (6.6%) 0.480 
Postoperative delirium 112 (12.4%) 90 (14.9%) 22 (7.3%) 0.001 
Postoperative myocardial Infarction 3 (0.3%) 2 (0.3%) 1 (0.3%) 1.000 
TIA/Stroke,… (CT-proofed) 52 (5.7%) 42 (7.0%) 10 (3.3%)  0.027 
Electrical cardioversion 57 (6.3%) 42 (7.0%) 15 (5.0%) 0.248 
CPR 26 (2.9%) 14 (2.3%) 12 (4.0%) 0.157 
Bronchomulmonary infection 58 (6.4%) 46 (7.6%) 12 (4.0%) 0.036 
Bacteriaemia/sepsis 31 (3.4%) 23 (3.8%) 8 (2.7%) 0.370 
Rethoracotomy 59 (6.5%) 34 (5.6%) 25 (8.3%) 0.123 
Sternal wound infection/VAC revision 12 (1.3%) 8 (1.3%) 4 (1.3%) 1.000 
Sinus rhythm 697 (78.0%) 467 (78.4%) 230 (77.2%) 0.690 
Atrial fibrillation 140 (15.7%) 90 (15.1%) 50 (16.8%) 0.515 
Other Rhythm 47 (5.3%) 32 (5.4%) 15 (5.0%) 0.832 
Pacemaker patient 59 (6.5%) 42 (7.0%) 17 (5.7%) 0.457 
Ventilation time, h 17 (12;31) 17 (12;30) 18 (13;31) 0.109 
ICU time, d 2 (1;4) 2 (1;4) 2 (1;4) 0.905 
Postoperative days 9 (7;13) 9 (7;13) 9 (7;13) 0.750 
7 d-Mortality 20 (2.3%) 12 (2.0%) 8 (2.7%) 0.527 
30 d-Mortality 36 (4.2%) 22 (3.9%) 14 (4.9%) 0.476 
Mortality POD 8 (2.0;19.5) 8.0 (2.5;18.5) 8.0 (2.0;25.0) 0.968 
Hospital Mortality  38 (4.3%) 22 (3.7%) 16 (5.4%) 0.239 
     Cardiac death 13 (32.5%) 7 (30.4%) 6 (35.3%) ---- 
     Cerebral death 6 (15.0%) 6 (26.1%) 0 (0.0%) ---- 
     Sepsis 4 (10.0%) 3 (13.0%) 1 (5.9%) ---- 
     MOF 17 (42.5%) 7 (30.4%) 10 (58.8%) ---- 
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3.2 First aim results: 
“To determine the predictors of PCS-AKI from the different surgical techniques used in 
ascending aorta replacement vascular surgery as moderate HCA, CPB and blood transfusion.” 
 
3.2.1 Hypothermic circulatory arrest time (HCAT) 
 The patients with PCS-AKI had a mean HCAT of 37.7 (±34.4) min  
The minimal HCAT was 9 min, and the maximum HCAT was 276 min (4 hours 36 min) 
 Patients without PCS-AKI had a mean HCAT of 22.5 min  
The minimal HCAT was 2 min, and the maximum HCAT was 182 min (3 hours 2 min) 
To measure the effect of HCAT on the kidney function, we had correlated it with the 
postoperative serial change in serum creatinine and glomerular filtration rate using 
Spearman's correlation coefficient and Student’s t-test   
The Spearman's correlation coefficient and P value between HCAT and (1) serial 
postoperative creatinine value increase from a preoperative baseline creatinine value; (2) the 
percent value of these increased from the baseline creatinine value and (3) the percent 
decrease in GFR from the preoperative baseline GFR at 6-12 and 12-20 hours after surgery 
and the 1st, 2nd, 3rd and 8th postoperative days (Tables 9, 10 and 11). The highest correlation 
coefficient for the three renal function deterioration parameters with HCAT was at 12-20 
hours after the surgery, with results of 0.268, 0.269 and 0.218, respectively, and the P values 
were less than 0.0001 for all of them.  
The more time that passed from the operation day, the lower the correlation coefficient. The 
correlation coefficients for the parameter on the 8th postoperative day were 0.052, 0.051 and 
0.042, respectively, with a P value less than 0.001 for all of them. 
The results are summarised in tables 9, 10 and 11 
Table 9; The relation between HCAT and the serial postoperative creatinine value change from the baseline 
creatinine just before surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.212 less than 0.0001 
Creatinine 12-20 h postoperative 0.268 less than 0.0001 
Creatinine 1. POD 0.236 less than 0.0001 
Creatinine 2. POD 0.202 less than 0.0001 
Creatinine 3. POD 0.185 0.0216 
Creatinine 8. POD (± 1 d) 0.052 less than 0.0001 
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Table 10; The relation between HCAT and percentage change in creatinine value from the baseline creatinine 
just before surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.214 less than 0.0001 
Creatinine 12-20 h postoperative 0.269 less than 0.0001 
Creatinine 1. POD 0.24 less than 0.0001 
Creatinine 2. POD 0.214 less than 0.0001 
Creatinine 3. POD 0.198 0.1287 
Creatinine 8. POD (± 1 d) 0.051 less than 0.0001 
 
Table 11; The relation between HCAT and the percentage decrease in GFR value from the baseline just before 
surgery 
 Correlation coefficient P-value 
GFR 6-12 h postoperative 0.174 less than 0.0001 
GFR 12-20 h postoperative 0.218 less than 0.0001 
GFR 1. POD 0.215 less than 0.0001 
GFR 2. POD 0.182 less than 0.0001 
GFR 3. POD 0.151 less than 0.0001 
GFR 8. POD (± 1 d) 0.042 less than 0.0001 
 
 
3.2.2 Cardiopulmonary bypass time:  
 Patients with PCS-AKI had a mean CPB time of 195 (± 67.5) min (3 hours 15 min) 
 The lowest CPB time was 86 min (1 hour 56 min), while the highest CPB time was 
466 min (7 hours 46 min) 
 Patients without PCS-AKI had a mean CPB time of 158 (±59.7) min (2 hours 38 min) 
 The lowest CPB time was 49 min, while the highest CPB time was 467 min (6 hours 
47 min) 
To measure the effect of CPB time on kidney function, we correlated CPB time with the 
postoperative serial change in serum creatinine and glomerular filtration rate using 
Spearman's correlation coefficient and Student’s t-test   
The Spearman’s correlation coefficient and the P-value between the CPB duration and (1) 
serial postoperative creatinine value increased from a preoperative baseline creatinine value; 
(2) the percent value of those increased from the baseline creatinine value and (3) the percent 
decrease in GFR from the preoperative baseline GFR at 6-12 and 12-20 hours after the 
surgery, and on the 1st, 2nd, 3rd and 8th postoperative days (Tables 12, 13 and 14). The highest 
correlation coefficient for the three renal function deterioration parameters with CPB duration 
was at 6-12 hours after surgery, with results of 0.306, 0.308, and 0.288, respectively; the P 
values were less than 0.0001 for all of them. 
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The more time that passed from the operation day, the lower the correlation coefficient. The 
correlation coefficient for the parameters on the 8th postoperative day were -0.022, -0.014, and 
-0.014, respectively, with a P value of less than 0.001 for all of them.  
The results are summarised in tables 12, 13 and 14 
Table 12; The relation between CPB time and the serial postoperative creatinine value change from the baseline 
creatinine just before the surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.306 less than 0.0001 
Creatinine 12-20 h postoperative 0.285 less than 0.0001 
Creatinine 1. POD 0.271 less than 0.0001 
Creatinine 2. POD 0.240 less than 0.0001 
Creatinine 3. POD 0.186 less than 0.0001 
Creatinine 8. POD (± 1 d) -0.022 less than 0.0001 
 
 
 
Table 14; Relation between CPB time and the percentage decrease in GFR value from the baseline just before 
surgery 
 Correlation coefficient P-value 
GFR 6-12 h postoperative 0.218 less than 0.0001 
GFR 12-20 h postoperative 0.198 less than 0.0001 
GFR 1. POD 0.202 less than 0.0001 
GFR 2. POD 0.167 less than 0.0001 
GFR 3. POD 0.133 less than 0.0001 
GFR 8. POD (± 1 d) -0.014 less than 0.0001 
 
 
3.2.3 Transfusion:  
Patients who had PCS-AKI had received a mean erythrocyte concentrate (EC) of 4.73 units. 
However, the patient who did not have PCS-AKI had received a mean of 2.42 units.  
To measure the effect of perioperative blood transfusion on the kidney function, we correlated 
the number of erythrocyte concentrates transferred perioperatively for each patient with the 
postoperative serial change in serum creatinine and glomerular filtration rate using 
Spearman's correlation coefficient and Student’s t-Test   
Table 13; The relation between CPB time and percentage change in creatinine value from the baseline 
creatinine just before surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.308 less than 0.0001 
Creatinine 12-20 h postoperative 0.288 less than 0.0001 
Creatinine 1. POD 0.278 less than 0.0001 
Creatinine 2. POD 0.265 less than 0.0001 
Creatinine 3. POD 0.210 less than 0.0001 
Creatinine 8. POD (± 1 d) -0.014 less than 0.0001 
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The Spearman’s correlation coefficient and P value between the number of EC-units 
transfused and (1) serial postoperative creatinine values increase from a preoperative baseline 
creatinine value and (2) serial percent value of the increase from the baseline creatinine value 
at 6-12 and 12-20 hours after surgery, and on the 1st, 2nd, 3rd and 8th postoperative days 
(Tables 15 and 16). The highest correlation coefficient for the two renal function deterioration 
parameters with the EC-units number was at 12-20 hours after the surgery, with results of 
0.28 and 0.286, respectively, the P values were 0,0064 and 0.0001, respectively. This 
indicates that the more time passed from the operation, the lower the correlation coefficient, 
which indicates a better kidney function as we move from the blood transfusion and the OP 
procedures. The correlation coefficient for the parameter on the 8th postoperative day was 
0.098 and 0.094, respectively, with a P value of 0.0365 and 0.001, respectively. 
The results are summarised in tables 15 and 16. 
Table 15; The relation between No. of perioperative EC-units and the serial postoperative creatinine value 
change from the baseline creatinine just before surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.244 0.1514 
Creatinine 12-20 h postoperative 0.280 0.0064 
Creatinine 1. POD 0.267 0.0107 
Creatinine 2. POD 0.228 0.7664 
Creatinine 3. POD 0.217 0.5746 
Creatinine 8. POD (± 1 d) 0.098 0.0365 
 
Table 16; The relation between the No. of perioperative EC-units and percentage change creatinine value from 
the baseline creatinine just before the surgery 
 Correlation coefficient P-value 
Creatinine 6-12 h postoperative 0.249 0.0001 
Creatinine 12-20 h postoperative 0.286 0.0001 
Creatinine 1. POD 0.275 0.0001 
Creatinine 2. POD 0.235 0.0096 
Creatinine 3. POD 0.224 0.0001 
Creatinine 8. POD (± 1 d) 0.094 0.0001 
 
3.3 Second aim results  
“The incidence of AKI after ascending aorta and aortic arch replacement surgery with 
moderate HCA and CPB.” 
  
 Of the 1351 patients who underwent those surgeries, 206 patients (15.2%) developed 
PCS-AKI according to KDIGO criteria.  
 Incidence in females: of the 1351 patients, 453 were female, and 55 (12.1%) had PCS-
AKI  
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 The incidence of RRT in females: of the 55 females with PCS-AKI, 42 patients required 
RRT (76.4%) 
 Incidence in males: of the 1351 patients, 898 were male, and 151 (16.8%) had PCS-AKI.  
 The incidence of RRT in males: of the 151 males with PCS-AKI, 81 patients required 
RRT (53.64%) 
 
3.4  Third aim results 
“The outcome of PCS-AKI was measured using (A) the mortality and (B) ICU duration of the 
critically ill patients who underwent those surgeries.” 
 
(A) Mortality rate 
 206 Patients with PCS-AKI; of them:  
 57 (27.6%) patients died within 50 postoperative days  
 52 died within 30 postoperative days (25.2% of total AKI patients) 
 32 died within seven postoperative days (15.5% of the total AKI patients) 
 Of the 1145 patients without PCS-AKI, 46 were dead within 30 postoperative days (4%), 
showing that PCS-AKI increases the mortality rate by more than six times. 
 Of the 57 Patients who died PCS-AKI, 51 (89.5%) had a new postoperative RRT 
 The mortality rate in women with PCS-AKI was 43.6% (24 women of the 55 with PCS-
AKI died)   
 The mortality rate in men with PCS-AKI was 21.8% (33 men of the 151 with PCS-AKI 
died)   
 
(B) Intensive care unit (ICU) stay by patients with and without PCS-AKI: 
 Patients with PCS-AKI in general (with RRT and without RRT) had an average ICU stay 
of 13.2 (± 13.3) days, whereas PCS-AKI patients who required RRT have an average 
ICU stay of 16.8 (± 14.9) days. However, the PCS-AKI patients who did not require RRT 
had an average ICU stay of 7.8 (± 7.8) days. 
 Patients without PCS-AKI had an average ICU stay of 4 (±5.3) days. 
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3.5 Fourth aim results 
The (A) PCS-RRT prediction methods and (B) the risk factors were evaluated by serial 
measurement of the different parameters and risk factors involved in those prediction modes 
using the right statistical evaluation for them; this subsequently leads to early prediction and 
intervention as well as the avoidance of them when possible, resulting in decreasing the 
incidence of postoperative AKI by trying to avoid those risk factors and in patients with 
unavoidable risk factors by early intervention using the early prediction methods.  
 
(A) Evaluation of the PCS-RRT predictions score items (Table 2): 
 Gender:  
 Incidence in females: of the 1351 patients, 453 were female, and 55 had PCS-AKI 
(12.1%). 
 The incidence of RRT in females: of the 55 females with PCS-AKI, 42 required RRT 
(76.4%). 
 Incidence in males: of the 1351 patients, 898 were male; of them, 151 had PCS-AKI 
(16.8%). 
 The incidence of RRT in males: of the 151 males with PCS-AKI, 81 required RRT 
(53.64%). 
 
 Chronic obstructive lung disease (COPD) :  
 Of the 1203 patients without COPD, 175 (14.5%) had PCS-AKI.  
 Of the 137 patients with COPD, 24 (17.5%) had PCS-AKI. 
 
 Diabetes mellitus (DM): 
 Of the 1199 patients without (DM), 166 (13.8%) had PCS-AKI.  
 Of the 84 patients with DM on oral therapy, 15 (17.8%) had PCS-AKI. However, those 
on insulin therapy showed a marked increase in PCS-AKI, where 13 of the 37 patients 
with insulin-dependent DM (35%) had PCS-AKI. 
 
 Chronic kidney insufficiency (CKD) (basal creatinine - eGFR): 
 Of the 285 patients with CKD, 102 (35.8%) have PCS-AKI. 
 Of the 1062 patients without CKD, 101 (9.5%) had PCS-AKI. 
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 Left ventricle ejection fraction (LV-EF): 
 Of the 873 patients with good LV-EF (LV-EF equal to or more than 55%), 103 (11.8%) 
had developed PCS-AKI. 
 Of the 140 patients with light restricted LV-EF (LV-EF between 45% and 54%), 12 
(8.57%) developed PCS-AKI.  
 Of the 110 patients with middle restricted LV-EF (LV-EF between 30% and 44%), 26 
(23.6%) had PCS-AKI.  
 Of the 33 patients with high restricted LV-EF (LV-EF less than 30), 5 (15.15%) had PCS-
AKI. 
 
 Myocardial infarction (MI) (within 2 days): 
 Of the 25 patients with preoperative MI (within two days before the surgery), 7 (28%) 
had PCS-AKI. 
 Of the 1316 patients without preoperative MI, 195 (15%) had PCS-AKI. 
 
 Cardiogenic shock (CS): 
 Of the 32 patients with preoperative CS, 16 (50%) had PCS-AKI. 
 Of the 1306 patients without preoperative CS, 186 (14.2%) had PCS-AKI. 
 
 Preoperative use of intra-aortic balloon pump (IABP) 2 (pre-operative 
cardiopulmonary status): 
 There were 1253 who were stable without circulatory system medication; of them, 164 
(13%) had PCS-AKI. 
 In total, 50 patients were stable with a minimal dose of circulatory system medication; of 
them, 16 (32%) had PCS-AKI. 
 Of the 34 patients who were stable with a high dose of circulatory system medication, 19 
(55%) had PCS-AKI. 
 There were 5 patients with IABP, 4 (80%) of which had PCS-AKI.  
 
 Previous cardiac surgery: 
 Of the 134 patients with previous cardiac surgery, 34 (25.4%) had PCS-AKI.  
 Of the 1193 patients without previous cardiac surgery, 166 (14%) had PCS-AKI. 
 
 Emergent surgery: 
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 Elective operation: of the 930 patients, 88 (9.46%) had PCS-AKI.  
 Urgent operation: of the 103 patients, 15 (14.56%) had PCS-AKI.  
 Emergency operation: of the 316 patients, 103 (32.6%) had PCS-AKI.  
 
 Surgery type (CABG / valve replacement) 
 With CABG surgery: 
 Of the 319 patients who underwent a superimposed bypass operation simultaneously, 
55 (17.2%) had PCS-AKI.  
 Of the 540 patients without a bypass operation, 92 (17.03%) had PCS-AKI.  
 Aortic valve replacement surgery: 
 Of the 791 patients who did not undergo a superimposed aortic valve replacement 
surgery simultaneously, 143 (18.07%) had PCS-AKI.  
 Of the 559 patients with a superimposed aortic valve replacement surgery 
simultaneously, 63 (11.27%) had PCS-AKI.  
 
(B) Other Risk factors (Table 3): 
 Peripheral arterial disease (PAD): 
 Of the 1268 patients without PAD, 187 (14.7%) had PCS-AKI.  
 Of the 69 Patients with PAD, 11 (16%) had PCS-AKI.  
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4. Discussion 
 
4.1 First aim discussion:  
To determine predictors of PCS-AKI from the different surgical techniques, and to assess 
which surgical procedures increase the risk of developing a PCS-AKI and considering those 
techniques as an adjustable risk factor that could be modulated or when they are necessary for 
the surgery without modulation then to be used in our early prediction scores for PCS-AKI. 
From those adjustable surgical techniques are (1) HCAT, (2) CPB time and (3) Blood 
transfusion.  
In our study, we measured the effect of the three surgical techniques on kidney function by 
correlating them to the postoperative kidney function using Spearman’s Correlation 
coefficient and the t-test P-value.  
The kidney function deterioration parameters were taken principally from the basic items in 
the KDIGO criteria (Table 1) which are: 
 The increase in SCr (Postoperative SCr at X – Preoperative SCr);  
 The percent increase in SCr (
(Postoperative SCr at X – Preoperative SCr)
Preoperative SCr
 x 100); 
 The percent decrease in GFR (
(Preoperative GFR – Postoperative GFR at X)
Preoperative GFR
 x 100). 
(X is the postoperative time when the SCr and the GFR were measured. Those include 6-12 
hours and 12-20 hours postoperatively and the 1st, 2nd, 3rd and 8th postoperative days)  
 
4.1.1 Hypothermic circulatory arrest time (HCAT) 
Most cardiac surgical procedures can be accomplished using cardioplegia-induced cardiac 
arrest and cardiopulmonary bypass (CPB) to maintain perfusion of other organs. In some 
situations, however, the underlying pathology or the nature of the surgery proposed 
necessitates complete cessation of the circulation as in aortic arch replacement surgeries. The 
use of profound systemic hypothermia to preserve organ function during cessation of the 
circulation is termed deep/moderate hypothermic circulatory arrest (HCA). The technique 
provides excellent operating conditions while reducing the consequences of organ ischemia 
and injury when blood flow is inadequate.  
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In renal transplantation, hypothermia is the dominant treatment to reduce metabolic rate and 
oxygen demand in donor's kidneys, to prolong ischemic tolerance, and to preserve organ 
viability(147).  Renal hypothermia prolongs ischemic tolerance during aortic occlusion by the 
same mechanism(148) and is an established adjunct to reduce kidney injury in aortic surgery. In 
addition to moderate systemic hypothermia, all patients had one-time renal perfusion with 4 C 
solution to rapidly cool the kidneys when the visceral segment of the aneurysm was opened. 
Renal perfusion also reduced systemic temperature 1 to 2 C. Hypothermia does not reliably 
protect if renal ischemia times are prolonged (>75 minutes), at least with cross-clamp 
technique, unless kidneys are perfused at intervals to keep the temperature shallow (148). 
HCA is typically undertaken at mild to moderate systemic hypothermia (typically a 
nasopharyngeal temperature of 25–36°C), and more challenging operations may require more 
profound hypothermia (15-24°C) to allow periods of low blood flow or circulatory arrest. 
Most patients tolerate 30 min of HCA without significant neurological dysfunction, but when 
this is extended to longer than 40 min, there is a marked increase in the incidence of brain 
injury. Above 60 min, the majority of patients will suffer irreversible brain damage, although 
a small number of patients can still tolerate this. More extended periods of HCA could be 
tolerated in neonates and infants compared with adults. It should be borne in mind that 
neurological injury may occur as a result of prolonged CPB and rewarming. 
However, regarding PCS-AKI, we found in this analysis that the average HCAT for patients 
who developed PCS-AKI was 37.7 (± 34.4) min, which is nearly 15 min more than the 
average of patients who did not develop PCS-AKI, with an average of 22 min.  
The Spearman's correlation coefficient between HCAT and the three renal function 
deterioration parameters of KDIGO criteria show a weak relation postoperatively, however, 
this relation was decreasing progrediently as time passed from the operation day which 
indicates an apparent recovery from PCS-AKI as we proceed further from the HCA, in 
addition to that the P values between them were 0.0001 which are extremely significant. (data 
are summarised in tables 9,10, 11 in the result section). With these results the effect of HCA 
on PSC-AKI could not be declined; however, more clinical trials are needed to clear the 
different pathophysiology.  
Some studies have found that HCA is not an independent risk factor for PSC-AKI as in 
Englberger et al.(146)  who stated that thoracic aortic surgery could be performed with low rates 
of AKI, comparable to other cardiac surgery procedures. They stated as well that HCA and 
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preoperative SCr are not independent risk factors for PCS-AKI, rather the risk estimation for 
PCS-AKI require multivariable prediction.  
Other many studies have agreed with our finding that HCA influences PSC-AKI; however, 
they have different pathophysiological reasons that lead to this insult where some blame the 
Hypothermia and its degree, while others blame the rewarming mechanism itself rather than 
the hypothermia. 
In a recent randomised trial by Boodahwani et al.(74) stated in data from two controlled trials, 
with more than 450 patients, demonstrate that in a routine CABG population, PCS-AKI 
occurred commonly (16%). Sustained mild intraoperative hypothermia did not appear to have 
a nephroprotective effect, as determined by postoperative SCr levels. On the other hand, 
rewarming from 32° to 37°C during a period of 10 to 15 minutes resulted in elevated 
postoperative SCr levels and a higher incidence of PCS-AKI compared with control patients 
rewarmed to 34°C. In addition to rewarming, CPB time and the presence of diabetes were 
predictors of renal dysfunction after CABG. In study 2, postoperative serum creatinine levels 
were similar between the hypothermic and normothermic groups (p 0.44), and there was no 
difference in the incidence of PCS-AKI between groups (hypothermic, 20% vs normothermic, 
15%; p 0.28), suggesting that rewarming, rather than cooling, is responsible for PCS-AKI. 
Based on such data, the rewarming rate may be a critical factor regarding suitable equilibrium 
of oxygen supply and demand in cardiac surgery with hypothermia.  
This was also confirmed by an experimental model in which during the restoration of 
normothermia, hypoperfusion of the outer part of the kidney cortex may happen with possible 
damage to these nephrons during the increased metabolic demands of rewarming. Moreover, 
the high perfusion of the kidney could amplify the harmful effects of rewarming. 
Nussmeier et al.(73) found aswell that rewarming, and the rate of rewarming, rather than the 
degree of temperature achieved may also be involved in the pathogenesis of organ injury; this 
rewarming is related to ischaemia-reperfusion injury.  
Although many studies had and are still investigating this topic, some cardiac surgeries are 
also performed in normothermic conditions, and there are still significant conflicting results of 
hypothermia versus normothermia regarding PCS-AKI. 
A possible reason for this discrepancy is how body temperature is measured. Monitoring 
nasopharyngeal, bladder or rectal temperature has a limited pathophysiological significance, 
since such measurements are reliant on factors such as body habitus, the percentage of body 
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fat, and ambient temperature, and may not provide a realistic assessment of the temperature of 
the blood which directly interacts with organs.  
Nussmeier et al.(73) found that the arterial temperature rather than core temperature gives a 
better estimation of jugular bulb temperature, which reflects the temperature of the central 
nervous system. 
Furthermore, in AORTA-study by Sansone et al.(149), the population was subdivided into 
various groups according to the HCAT. The outcomes are emphasized in figure 5, a group of 
five patients with HCA less than 15 min (30-day mortality 0%, AKI 0%), another group 
(13 patients) with HCA between 15-30 min (30-day mortality 15.3%, AKI 30.7%) and the last 
group (19 pat.) with HCA greater than 30 min (30-day mortality 42%, OR 5.8 p = 0.038; AKI 
52.6% OR 2.8 p = 0.05). These data emphasise the benefits of as short as possible HCA in 
terms of short-term survival and renal outcomes (Figure 5). 
Figure 5; Thirty-day mortality and AKI by hypothermic circulatory arrest times; ARF = acute renal failure; HCA 
= hypothermic circulatory arrest. 
In addition according to degrees of HCA, as illustrated in figure 6, they identified 12 patients 
who underwent HCA less than 21°C (30-day mortality 33.3%; AKI 50%, p = ns), another 
group of 23 patients  in whom we performed HCA between 21–25°C (30-day mort 26%; AKI 
34,7%, p = ns), and a last group of two patients with HCA greater than 25°C (30-day 
mortality 0%; AKI 0%). These data seem to suggest a better 30-day survival and better renal 
outcomes with lesser hypothermia. 
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Figure 6; Thirty-day mortality and AKI by hypothermic circulatory arrest temperature, C°. ARF = acute renal 
failure; NS = non-significant. 
The AORTA-Study bring out a better 30-day survival and better renal outcomes in case of 
shorter HCA and a lesser degree of hypothermia. The option of lesser and shorter 
hypothermia may be beneficial. 
Nota H. et al. (150) was trying in his analysis to find out the risk factors related to PCS-AKI 
with selective cerebral perfusion (SCP) and mild HCA. The AKI group had a significantly 
longer mean operation time, CPB time, cardiac arrest time, mild HCA time and SCP time 
compared with the non-AKI group (Figure 7). The logistic regression analysis identified CKD 
and mild HCA >60 min as independent risk factors for PSC-AKI (Figure 8) 
 
  AKI (n = 50)  Non-AKI (n = 66)  P-value  
Operation time (min)  293.0 ± 73.4  253.6 ± 67.5  0.005*  
CPB time (min)  164.9 ± 46.9  140.4 ± 43.5  0.002*  
Cardiac arrest time (min)  93.8 ± 29.8  78.5 ± 26.5  0.003*  
Mild HCA time (min)  59.2 ± 21.5  48.5 ± 17.8  0.004*  
SCP time (min)  105.3 ± 31.0  94.3 ± 25.5  0.040*  
Tympanic temperature at initiation of mild HLBCA (°C)  24.8 ± 1.4  25.1 ± 1.5  0.171  
Lowest tympanic temperature (°C)  23.7 ± 1.2  23.6 ± 1.1  0.421  
Bladder temperature at initiation of mild HLBCA (°C)  29.6 ± 2.6  29.7 ± 2.7  0.701  
Lowest bladder temperature (°C)  27.7 ± 2.1  27.7 ± 2.1  0.959  
Operation time >360 min  9 (18.0%)  4 (6.0%)  0.044*  
Mild HLBCA time >60 min  23 (46.0%)  13 (19.6%)  0.002*  
Figure 7; perfusion data; AKI: acute kidney injury; CPB: cardiopulmonary bypass; HCA: hypothermic 
circulatory arrest. 
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Variable  P-
value  
Odds 
ratio  
95% Confidence 
Intervall  
CKD (eGFR <60 ml/min/1.73 m2)  0.014*  2.949  1.24–7.01  
Mild HCA >60 min  0.028*  2.937  1.12–7.65  
Tympanic temperature at initiation of mild HCA 
(°C)  
0.225      
Lowest tympanic temperature (°C)  0.581      
Bladder temperature at initiation of mild HCA (°C)  0.747      
Lowest bladder temperature (°C)  0.958      
Figure 8; Multivariate analysis for PCS-AKI; AKI: acute kidney injury; CKD: chronic kidney disease; eGFR: 
estimated glomerular filtration rate; HCA: hypothermic circulatory arrest. 
 
4.1.2 Cardiopulmonary bypass (CPB) time 
More than 60 years ago, the cardiopulmonary bypass machine was introduced to the medical 
field. This introduction made complicated cardiac surgery possible without high risk; 
however, already in the 1960s, the association between CPB and AKI became apparent(75). 
The materials and techniques have improved, but CPB is still considered to have a massive 
influence on PCS-AKI. 
CPB time was mentioned in many studies as a directly proportional modulated risk factor (or 
surgical technique) to the incidence of PCS-AKI.  
In our study, the average CPB duration for patients who developed PCS-AKI was 3 hours 15 
min (195 ± 67.5 min), 35 min longer than the average of patients who did not develop PCS-
AKI, with an average of 2 hours 38 min (158 ±59.7 min).  
Although that the Spearman's correlation coefficient showed weak relations between the CPB 
time and the three kidney deterioration variable of KDIGO criteria postoperatively, There was 
a sequential decrease in the Spearman’s correlation as more time passed from the operation 
day, which indicates an improvement in kidney function as we move away from the CPB. In 
addition to that the P values between them showed extremely significant relations (0.0001 for 
all relations; data are summarised in tables 12,13 and 14). Those results showed a clear proof 
that the CPB time has a direct effect on the postoperative kidney functions deterioration.  
The Pathophysiology PSC-AKI after CPB is multivariable. The generation of SIRS, 
activation of the immune system, as well as hypotension and other adverse physiologic 
processes caused by CPB exposure explain why the incidence of PCS-AKI correlates with the 
duration of CPB. A recent meta-analysis of 9 studies reported that 756 of the 12,466 patients 
(6.06%) who underwent CPB developed PCS-AKI by AKIN definition and had longer CPB 
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times. The average CPB time for patients who developed PCS-AKI compared to those who 
did not was significantly longer(76) (23.18 min, 95% CI 16.7–29.66; P < 0.0001).  
Other studies indicate that longer CPB and cross-clamp times are strongly associated with an 
increased incidence of PCS-AKI. A safe cut-off time has not been determined(76). 
 
Pump flow during CPB 
The goal of CPB is to maintain regional perfusion at a level that supports optimal organ 
function(77). The CPB flow rate recommendation of 1.8-2.2 l/min/m2 is based on experimental 
calculations of global oxygen consumption at different perfusion rates(78). However, it is not 
known what the regional flow rates are with this recommendation, and generally, flow rates 
are maintained at the level of the standard cardiac index, 2.2-2.4 l/min/m2.  
There is debate as to whether a pulsatile flow preserves kidney function better than a non-
pulsatile flow in CPB. In one prominent study, pulsatile flow demonstrated no protection to 
the kidneys compared with the non-pulsatile flow(79). However, another more recent research 
showed less acute renal insufficiency and significantly improved whole-body perfusion in the 
elderly undergoing CPB with intra-aortic balloon pump (IABP) induced pulsatile flow(80).  
It was also shown that pulsatile flow lowers peripheral vascular resistance, maintaining better 
microcirculation and tissue metabolism, and decreasing tissue oedema(81).  
Despite the theoretical benefits of the pulsatile flow, almost all centres perform CPB using 
non-pulsatile pumps. 
 
Perfusion pressure during CPB 
CPB is associated with significant clinical haemodynamic changes that are related to the 
unique pressure and flow characteristics of CPB systems. Maintaining regional perfusion is 
the ultimate goal of non-pulsatile CPB flow. This perfusion is required for the support of 
optimal cellular and organ function. 
The flow rate and perfusion pressure determine regional blood flow in CPB. The ideal 
perfusion pressure to support adequate local oxygen transfer to the kidneys is unknown, and 
in general, an average perfusion pressure of 50 to 70 mmHg with normal cardiac output is 
maintained to ensure sufficient renal protection(15).  
Also, it is unknown whether these recommended flow rates and pressure limits are sufficient 
to ensure an optimal renal blood flow in patients with preoperative kidney injury, or in 
patients with pre-existing ATN and the possible loss of autoregulation(15). 
One study looked at CPB mean arterial pressure (MAP) ranges of 40 to 80 mmHg in elderly 
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patients and found no correlation with postoperative renal dysfunction(82).  
A study in patients with normal preoperative renal function showed an association between 
postoperative AKI and longer CPB time, lower perfusion flow, and extended periods on CPB 
at pressures below 60 mmHg(83).  
Ono et al. measured the excursions of MAP during CPB below the limit of autoregulation, 
and found that MAP at the limit of autoregulation and the duration and degree to which MAP 
was below the autoregulation threshold were independently related to AKI, although the 
absolute MAP did not differ between patients with AKI and those without kidney injury(84).  
Moreover, it was proved that a MAP change (preoperative minus intraoperative MAP) more 
than 26 mmHg was independently related to AKI in high-risk patients(85). 
 
Embolism during CPB 
During macroscopic and microscopic CPB, both gaseous and particulate emboli are generated 
and may lead to organ injury. The importance of embolism during CPB is confirmed by the 
fact that post-mortem studies have documented atheroemboli in the brain, heart, 
gastrointestinal tract, kidney, and lower extremity tissues of patients who had undergone 
CPB(86). 
Another in vivo method was applied to correlate between the number of cerebral emboli and 
postoperative stroke, and kidney injury was demonstrated(87). When pulses of embolic signals 
were registered with transcranial Doppler, pulses of embolic signals were obtained during 
aortic manipulation, suggesting that atherosclerotic aorta is a risk for stroke and AKI(87). 
Air is another source of emboli. It may enter the left side of heart when the left side of the 
heart is open, for example during valve surgery, or enter from the right side through an open 
foramen ovale. “De-airing” manoeuvres are applied to remove the air, and the use of carbon 
dioxide aids to remove trapped air from the heart as it is more soluble in blood than nitrogen, 
the main component of air(88). Echocardiography is helpful to detect and to aid the removal of 
residual air(89). 
 
Inflammatory system 
CPB activates a systemic inflammatory response, which in some patients clinically manifests 
as a syndrome (SIRS)(90). 
Cardiac surgery with a CPB pump elevates more systemic inflammatory factors than off-
pump operations, indicating that CPB itself aggravates SIRS(91). 
The main triggers of CPB-associated SIRS are the direct contact of blood with the artificial 
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surface of the bypass circuit, the development of ischaemia-reperfusion injury, and the 
presence of endotoxaemia(92-94). 
Other possible provoking factors are operative trauma, non-pulsatile blood flow, mediastinal 
shed blood during CPB, and pre-existing left ventricular dysfunction(15). 
The increased level of circulating inflammatory mediators may elicit endothelial dysfunction 
and the initiation of AKI amplified by alterations in renal perfusion(95).  
 
Ultrafiltration during CPB 
Ultrafiltration is a standard method to remove fluid overload during CPB. It is frequently used 
in paediatric cardiac surgery and is progressively being used more in adult cardiac surgery, 
both perioperatively and postoperatively. There are no data, however, on whether this 
procedure improves renal outcome in adult cardiac surgery, but it is known that ultrafiltration 
reduces the adverse effects of haemodilution, and therefore reduces the need for transfusion 
and also may decrease inflammation(96). 
 
Haemodilution during CPB 
During CPB, haemodilution decreases blood viscosity, improving regional blood flow in the 
setting of hypoperfusion and hypothermia, and minimises the need for blood transfusion. 
Increases in regional blood flow are expected to compensate for the decreased oxygen-
carrying capacity of the blood. The impairment of oxygen transport to the hypoxic kidney 
medulla or the increase in systemic inflammatory mediators caused by ischaemia is thought to 
play a vital role in the pathogenesis of PCS-AKI(15,77). 
 In a retrospective study of 1,760 CPB surgery patients, it was found that intraoperative 
anaemia of haematocrit less than 24% was significantly related to an increased occurrence of 
PCS-AKI(97). 
AKI risk seemed to increase when both anaemia and hypotension occurred during CPB, 
compared with anaemia alone(81).  
Karkouti et al.(98) showed that moderate haemodilution (haematocrit concentration 21–25%) 
was associated with the lowest risk of PCS-RRT, and the risk increased as the haematocrit 
concentration deviated from this range in both directions.  
In a recent prospective study, in the low-haematocrit group, <24% presented an increase in 
PCS-AKI and tissue hypoxemia (lactate) markers(99).  
These studies suggest that a higher risk of PCS-AKI accompanies a haematocrit level of 
<24%. The need for randomised controlled studies remains. 
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Haemolysis during CPB 
Intravascular haemolysis is a typical result of CPB(100). In haemolysis, there are several 
contributing factors to kidney injury, such as the loss of red blood cell (RBC) mass, impaired 
endothelial function, oxidative damage, and cytotoxic tubular damage(101).  
Haptoglobin scavenges circulating free haemoglobin (fHb), but when its capacity is saturated, 
fHb binds to nitric oxide (NO) derived from endothelium, leading to decreased NO-
bioavailability, consequently increasing vascular resistance and decreasing organ 
perfusion(102). 
In a recent study of cardiac surgery patients, there was a significant correlation between 
haemolysis, NO consumption, and kidney tissue damage after CPB and surgery(101).  
Also, the structure of RBCs can be damaged, which diminishes their ability to enter small 
vessels and reduces their contact with vessel walls, leading to organ ischaemia(100). 
In a setting of CPB, several mechanisms contribute to the destruction of RBCs: shear stress, 
blood-air and blood-endothelial interface, and positive and negative pressures. The primary 
source of fHb is suction from the operative field and active suction from heart chambers. The 
amount of air that is aspirated together with the blood increases red cell fragility(104).  
CPB time is also directly related to the degree of hemolysis(105). 
There is no evidence of the advantage of the rollers over the centrifugal pumps concerning 
haemolysis(100).  
The suggested strategies to prevent haemolysis during CPB are to avoid the excessive use of 
suction, use a separate cardiotomy reservoir to avoid damaged RBCs and fHb, administer 
haptoglobin or NO-donors to compensate for the enhanced NO consumption, and apply a 
super high-flux haemofilter to remove fHb(101). 
During CPB blood sucked from the operative field can be collected to the venous reservoir 
and returned directly to the patient through the bypass circuit or after processing blood with a 
cell-saving device. Cell saving devices retain RBCs and remove fHb, inflammatory 
mediators, fat emboli, and heparin, as well as plasma and platelets, as mentioned before.  
At present, there is no proof that this cell saving technique has an effect on renal outcome 
after cardiac surgery(101). 
 
4.1.3  Blood transfusion 
Perioperative RBC transfusion is considered to be a risk factor for PCS-AKI in susceptible 
patients, such as those with preoperative kidney disease or anaemia(106); in our study, we 
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found that patients who received more EC-units via transfusion perioperatively have a higher 
risk of developing PCS-AKI, as patients who had PCS-AKI received a mean of 4.73 EC-units 
while those who did not have PCS-AKI received a mean of 2.42 EC-units perioperatively. 
The Spearman’s correlation coefficient and P value for the number of EC-units transfused and 
serial postoperative creatinine values increase from a preoperative baseline creatinine value 
and serial percent value of these increase from the baseline creatinine value at 6-12 and 12-20 
hours after surgery, and on the 1st, 2nd, 3rd and 8th postoperative days (Tables 15 and 16). The 
highest correlation coefficient for the two renal function deterioration parameters with the 
EC-units number was at 12-20 hours after the surgery, with results of 0.28 and 0.286, 
respectively, the P values were 0,0064 and 0.0001, respectively. This indicates that the more 
time passed from the operation, the lower the correlation coefficient, which shows a better 
kidney function as we move from the blood transfusion and the OP procedures. The 
correlation coefficient for the parameter on the 8th postoperative day was 0.098 and 0.094, 
respectively, with a P value of 0.0365 and 0.001, respectively. 
There is a big discussion here over whether the development of PCS-AKI is because of the 
transferred blood itself or as a result of the tissue hypoxia result from blood loss during the 
operation or a predisposing anaemia; many studies have been working in this field trying to 
clear it as much as possible.  
The PCS-AKI relation to the blood transfusion was explained in other studies by the long 
duration blood concentrate could be stored when it is proved; the stored RBCs in these blood 
concentrates after 14 days became less formable, undergo ATP and 2,3-diphosphoglycerate 
depletion, lose their ability to generate NO, have increased adhesiveness to vascular 
endothelium, release pro-coagulant phospholipids, and accumulate pro-inflammatory 
molecules, free iron and haemoglobin. Hence, instead of improving oxygen delivery, they 
may cause organ injury(107-110). 
The transfusion of stored RBCs may elicit harmful effects, such as inflammation, renal 
hypoxia, and oxidative stress(106). 
Patients with preoperative anaemia are especially more susceptible to transfusion-related AKI 
than non-anaemic patients(77). 
In a recent study, prophylactic RBC transfusion reduced perioperative anaemia and RBC 
transfusions and possibly reduced plasma iron levels(111).  
Interventions to avoid perioperative blood transfusion are recommended, such as drugs that 
increase preoperative blood volume or decrease postoperative bleeding, the use of devices that 
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conserve blood, and interventions that protect the patient’s blood from the stress of 
operation(111). 
Anaemia 
Studies have shown that perioperative anaemia in cardiac surgery is independently associated 
with various adverse outcomes, including PCS-AKI(112,113).  
Anaemia may contribute to kidney injury by reducing renal oxygen delivery, worsening 
oxidative stress, and impairing haemostasis. 
Tissue oxygen delivery is directly related to arterial oxygen content, which is primarily 
dependent on the haemoglobin concentration(114). 
The adverse consequences of anaemia are likely increased more in the course of cardiac 
surgery, as, for reasons outlined earlier, the kidney is more prone to renal hypoperfusion(115). 
Anaemia decreases oxygen delivery to kidneys and particularly the outer part of the renal 
medulla, where the normal partial pressure of oxygen in the renal tissue is very low(114). 
Anaemia may enhance renal oxidative stress because RBCs serve essential antioxidant 
functions(114). 
Anaemia leads to haemostasis disequilibrium, as the normal platelet role is dependent on the 
presence of sufficient (but as yet undetermined) haemoglobin concentrations(116,117).  
In cardiac surgery, during which patients are already at an increased risk of bleeding due to CPB-
related haemostatic defects(118), the added burden of anaemia-induced platelet dysfunction may 
lead to excessive bleeding, which in turn may require several RBC transfusions and re-
exploration surgery, both associated with AKI. 
 
4.2 Second Aim discussion 
In the present study, out of 1351 patients, who underwent aortic surgery with moderate HCA 
and CPB, 205 (15.2%), according to the KDIGO criteria for AKI, showed either an increase 
in the serum creatinine value to more than 0.3 mg/dl (26.5µM) from the preoperative serum 
creatinine value within 48 hours or more than 1.5 times the preoperative serum creatinine 
value within 7 days; required a new postoperative RRT; or decreased their urine volume to 
less than 0.5 ml/kg/h for more than 6 hours and thus to an acute kidney injury.  
Male patients showed a slightly higher incidence of developing PCS-AKI than female patients 
with a ratio of 16.8%:12.1%.  
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Of the 205 patients who developed PCS-AKI, 123 (60%) had to be dialysed in the further 
course; females with PCS-AKI showed a higher incidence of RRT than males with the same 
PCS complication in a ratio of 76.4%:53.64%. 
Previous studies report a different PCS-AKI incidence ranging between 8.9% and 50% after 
cardiac surgeries, or a dialysis incidence rate ranging from 1–5% of patients who established 
PCS-AKI(7). The following table provides an overview of the incidence of AKI and mortality 
according to cardiac surgery from several studies. 
 Table 17 Various studies showing the incidence of PCS-AKI according to RIFLE, AKIN or KDIGO criteria 
Study Year 
published 
Patient 
Numbers 
Surgery 
type 
Incidence Diagnosis 
criteria 
In-hospital mortality 
rates of AKI vs non-
AKI 
Karkouti et 
al. (119) 
2009 3,500 CS three 
thresholds 
of AKI: 24, 
7, and 3%, 
respectively 
AKIN: 25, 50, 
and 75% decrease 
in eGFR within 1 
week 
 
three thresholds of 
AKI: 10, 25, vs non-
AKI 
Bagur et al. 
(120) 
 
 
2010 
 
 
 
213 
 
 
 
TAVI 
 
 
 
11.7% 
 
 
 
RIFLE: reduction 
of 25% in eGFR 
within 48 h 
 
28 vs.7.4% 
 
 
 
D’Onofrio et 
al. (121) 
 
 
 
2010 
 
 
 
 
2,488 
 
 
 
 
CS 
 
 
 
 
23.5% 
 
 
 
 
RIFLE: using 
peak 
postoperative SCr 
in the ICU 
5.5 vs 1.5% 
 
 
 
 
Swaminathan 
et al. (122) 
 
 
 
 
2010 
 
 
 
 
 
10,275 
 
 
 
 
 
CABG 
 
 
 
 
 
10.8% 
 
 
 
 
 
AKIN: a peak SCr 
≥50% above 
baseline within 
five days 
postoperatively 
n.k. 
 
 
 
 
Englberger et 
al. (123) 
2011 4,836 CS with 
CPB 
diagnosed 
by AKIN: 
26.3%; by 
RIFLE: 
18.9% 
defined by RIFLE 
and AKIN within 
seven days 
postoperatively 
RIFLE: 3.8 (R), 18.3 
(I), 19.4 (F) vs. 0.53% 
AKIN: 2.6 (I), 12.3 (II), 
44.6 (III) vs. 0.64% 
Robert et al. 
(124) 
2010 25,086 CS diagnosed 
by AKIN: 
30%; by 
RIFLE: 
31% 
AKIN and RIFLE AKIN: 4.1 (I), 14.2 (II), 
36.8 (III) vs. 1.3% 
RIFLE: 3.3 (R), 11.1 
(I), 36.4 (F) vs. 1.4% 
Brown et al. 
(125) 
2010 4,987 CS 39% AKIN HR: 1.54–6.13 (non-
AKI HR: 1) 
Li et al. (126) 2011 964 Elective 
CABG 
19.8% 
(7.9% in 
stage 1, 
3.5% in 
stage 2, and 
8.4% in 
stage 3) 
AKIN in-hospital mortality 
rate [15, 16]: OR 4.07; 
p<0.001(overall in-
hospital mortality rate 
5.1%) 
Parolari et al. 
(127) 
2012 3,219 CS with 
CPB 
8.9% AKIN n.k. 
Englberger et 
al. (128) 
2012 951 TV 30% RIFLE class (R, I, 
or F) within the 
6.5 (R), 17.2 (I), 54.4 
(F) vs. 1.5% 
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first seven days 
postoperatively 
Lagny et al. 
(129) 
 
2015 443 CAPG or 
MVR/AVR 
or both 
with CPB 
49.9% RIFLE: Elevated 
serum creatinine 
(AKI SCr) and 
oliguria (AKIUO) 
was observed in 
9.7 % and 40.2 %, 
2.37 % vs. 0.04 
CS = Cardiac surgery; eGFR = estimated glomerular filtration rate; HR = adjusted hazard ratio from Cox 
proportional hazard model; n.k. = not known; TAVI = trans-catheter aortic valve implantation; TV = tricuspid 
valve surgery. 
 
It is evident that there are significant differences in the reported incidence of PCS-AKI as well 
as the need for RRT. 
Isolated CABG surgery was reported with the lowest incidence of AKI, followed by valvular 
surgery and combined CABG with valvular surgery(135).  
D’Onofrio et al. described a PCS-AKI incidence of nearly 23.5% in the mixed patient 
population of cardiac surgery with CPB(121). Yamamoto et al. reported only 15% of 415 TF-
TAVI patients(131). Bagur et al. reported an AKI incidence of only 11.7%(120). A significantly 
higher incidence rate is described by the work of Lagny et al.,(129)at 49.9%. 
The significant differences in the incidence of PCS-AKI according to different studies can be 
explained by the different comorbidities of the patients studied, the type of cardiac surgical 
interference performed and the lack of a uniform definition of AKI, which has complicated 
the research in this field and made the results of comparisons confusing as there are various 
definition criteria used to identify patients with AKI (RIFLE, AKIN or KDIGO). Previous 
studies defined an AKI according to RIFLE criteria, while the more recent studies define the 
AKI according to the modified RIFLE criteria AKIN and later by KDIGO. In our study, an 
AKI diagnosis was based strictly on the renal function parameters according to the KDIGO 
AKI-Criteria (Figure 1). 
Further reasons for the different incidence of postoperative AKI can be explained by different 
perioperative and postoperative management as well as different times for the collection of 
renal function parameters.  
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4.3 Third aim discussion 
“The outcome of PCS-AKI by measuring (A) the mortality and (B) ICU duration of those 
critically ill patients who underwent those surgeries.” 
 
(A) Mortality rate 
AKI is an independent predictor of mortality after cardiac surgery (119,132). Prior studies proved 
that the AKIN and RIFLE criteria are accurate early predictors of death,(123,124) along with 
KDIGO in our analysis. 
According to our study, we found that PCS-AKI increases the postoperative 30-day mortality 
rate by 6.3 times, where the 30-day mortality rate percent ratio in patients with PCS-AKI and 
patients without was 25.2%:4%. 
Also, the seven-day mortality rate for patients with PCS-AKI was 15.5%, and the woman to 
man ratio with PCS-AKI mortality rate was 43.6%:21.8%. 
Applying AKIN, RIFLE or KDIGO criteria, the mortality rate (hospital discharge or 30-day 
mortality) is between 3.8 and 54.4% in patients who develop PCS-AKI and increases 
progressively with the degree of renal impairment (Table 17)(4). Recent studies reported that 
after cardiac surgery, even a slight increase in serum creatinine level has a significant effect 
on the postoperative mortality rates(132,133). Furthermore, long-term survival was significantly 
related to the duration of AKI(125), and the early recovery of renal function was associated 
with improved long-term survival after PCS-AKI(122).  
Older studies have demonstrated that the overall mortality after cardiac surgery ranges 
between 1% and 8%, but when PCS-AKI exists, a four-fold increase (up to 36%) in mortality 
rates were recorded(119). 
Furthermore, 45% of PCS patients surviving RRT, according to a recent retrospective study of 
2973 patients, remain dialysis-dependent, 33% may have partial renal recovery, and only 21% 
may have a complete renal recovery at the time of hospital discharge(25). 
Some studies have been performed to modulate the dialysis technique, as in Schiffl et al.,(134) 
who stated that the high frequency of haemodialysis of 5 times per week instead of 3 times 
increases the rapid recovery from AKI from 17 days ±6 to 9 days ±2, and decreases the 
mortality rate from 46% to 28%.  
Nuromohamed et al.(135) stated that an inadequate CRRT-Dose is directly associated with the 
high mortality rate, while KDIGO states that the recommended RRT dose by AKI is 20-25 
ml/kg KG/h. 
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Other studies have been performed to indicate the early criteria for starting dialysis and 
compared and defined the early and late start times when there is no absolute indication for 
dialysis present. In the study by Zarbock et al.,(136) the signs to an early start of RRT were: 
KDIGO stage 2; plasma neutrophil gelatinase-associated lipocalin (NGAL) >150 ng/mL; and 
one of the following: severe sepsis, use of vasopressors or catecholamines, refractory fluid 
overload, or the development or progression of non-renal organ dysfunction [Sequential 
Organ Failure Assessment (SOFA) score ≥ 2]. 
The “early” initiation of RRT, according to Zarbock et al., was done to patients treated by 
RRT within 8 hours from stage 2 AKI; the “delayed” initiation implied that RRT started 
within 12 hours of the diagnosis of stage 3 or any absolute indication for RRT, including the 
following: serum urea level >100 mg/dL; hyperkalaemia (>6 mEq/L) and/or with 
electrocardiography abnormalities; serum magnesium level >8 mEq/L; UO <200 mL/12 hours 
or anuria; and organ oedema in the presence of AKI resistant to diuretic treatment (one 
attempt with loop diuretics prior to randomisation).  
Zarbock et al. concluded that the “early” initiation of RRT for critically ill patients with AKI 
reduced mortality over the first 90 days over “delayed” initiation. 
 
(B) Intensive care unit duration for patients with and without AKI 
In our analysis, patients with PCS-AKI had a mean stay in the intensive care unit of 13.2 (± 
13.3) days, whereas patients who required RRT had an average ICU stay of 16.8 (± 14.9) 
days, however, the patients with PCS-AKI who did not require RRT had an average ICU stay 
of 7.8 ( ± 7.8) days 
Patients without PCS-AKI had a mean ICU stay of 4 (±5.3) days. 
Therefore, PCS-AKI increases the hospital stay by twice, up to 4 times (in case of RRT), the 
duration required without AKI, which has an immediate and economic effect on the hospital, 
patients and cost of stay.  
Another previous study(54) stated that the risk-adjusted average cost of care for patients 
undergoing surgery was $42,600 for patients with any AKI compared to $26,700 for patients 
without AKI. Also, patients with AKI were more likely to have other postoperative 
complications which increased the length of stay in ICUs and the hospital overall. 
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4.4  Fourth aim discussion 
In our study, we mentioned a scoring RRT prediction mode that used certain risk factors as an 
indication for early dialysis; on the other hand, we also mentioned other studies which 
identified some risk factors to be predictive risk factors for PCS-AKI. 
Postoperative RRT is closely related to the high mortality rate. Moreover, death is the most 
prominent fear of any patient who undergoes an operation. Patients who require RRT 
postoperatively have -according to our study- a high mortality rate more than 50%, Therefore, 
we consider it vital to re-evaluate the RRT prediction scores and use them for the early 
prediction of PCS-AKI and -RRT in our patients and to initiate the required therapy as soon 
as possible, trying to avoid as many complications as possible. 
In 2005, Thakar et al.(28), in 2006, Mehta et al.(20) and in 2007, Wijeysundera et al.(21) stated 
that some risk factors (and operations techniques will be discussed in Aim 1 results) 
mentioned in table 2 could predict the postoperative requirement of RRT.  
Also, other studies have identified some risk factors to be predictive of PCS-AKI (Table 3). 
Out of those risk factors, we have checked the following:  
 
(1) Gender:  
Female sex was only mentioned in the Thakar prediction score and some studies(20,23,24,32-36) 
as a risk factor. 
In our study, we found that it is an insignificant risk factor as the percentage of females who 
were operated on and developed PCS-AKI is lower than the male percentage, with a female to 
male ratio of 12.1%:16.8%. 
Therefore, the percentage of men who postoperatively suffer from AKI is higher than that of 
females. 
Hashemzadeh et al.(137) confirmed that male gender is a risk factor for PCS-AKI. 
Different studies have contradicting results about the gender; due to the insignificant 
difference between males and females who developed PCS-AKI (only 4%), we believe that 
gender is not a significant risk factor for PCS-AKI. 
 
(2) COPD was mentioned in the prediction scores of Thakar el at., Metha el at. and some 
studies(20,23,24,32-36) as a risk factor. 
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In our analysis, we found that there is a slight increase in PCS-AKI in COPD patients, where 
the incidence of PCS-AKI in patients who have COPD and those without was 17.5% and 
14.5%, respectively. 
Hashemzadeh et al.(137) stated that COPD is not a risk factor, as the risk of developing a PCS-
AKI in patients with COPD and those without was 7.8% and 8.8%, respectively. 
 
(3) Diabetes mellitus (DM) was mentioned in Thakar et al., Metha et al. and 
Wijeysundera et al. prediction scores, as well as some other studies(20,23,24,32-36) as a risk factor. 
Hashemzadeh et al.(137) found that the ratio of patients with DM and those without who 
developed PCS-AKI was 29.7%:18.5%. 
Moreover, in our study, the level of IDDM patients showed a marked increase in PCS-AKI, 
with a percent of 35%, whereas DM patients on oral therapy and no DM showed a 
significantly lower value of 17.8% and 13.8%, respectively.  
 
(4) Chronic kidney disease (CKD) or preoperative renal injury. With the application 
of CKD classification, most studies and prediction scores demonstrated that the degree of 
preoperative renal dysfunction, either with a high creatinine or low GFR value, parallel a 
proportionally increased risk of PCS-AKI and the requirement of RRT(20,23,24,32-36,126). 
In our study, the preoperative CRF or renal injury were very significant risk factors for PCS-
AKI and PCS-RRT. In the present study, patients with preoperative CRF showed an increase 
in PCS-AKI incidence with a percentage of 35.8% in comparison with patients without 
preoperative CRF who had a percentage of 9.5%. 
The focus of some studies was an assessment of the probability of PCS-AKI superimposed on 
CKD, while another focus was avoiding subclinical or silent AKI preceding surgery, in which 
the drugs used, especially contrast media-induced kidney injuries. When cardiac 
catheterisation and cardiac surgery occurred during the same hospitalisation period, there was 
an increased risk of postoperative AKI. This is likely due to the time needed for renal cell 
recovery before new insults to renal cells from the surgery itself(138). 
 
(5) Left ventricular ejection fraction (LV-EF). During the perioperative period, the 
volume status of the patients is of vital importance; according to different studies, cardiac 
output before, during or after surgery, is directly related to PCS-AKI incidence. This can be 
explained by the hyperactivity of the sympathetic nervous system, with the corresponding 
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activation of the renin-angiotensin-aldosterone (RAA) system, which increases renal 
vasoconstriction(32). 
LV-EF was mentioned in Thakar et al., and in the Wijeysundera et al. prediction scores as 
well as in the following studies (20,23,24,32-36) as a risk factor for PCS-AKI. 
Hashemzadeh et al.(137) mentioned that patients with LV-EF less than 30% have evidently a 
higher risk of developing PCS-AKI (14.1%) than patients with a higher LV-EF (5.5%).  
Pieri et al.(139) confirmed that patients with low LV-EF (≤40%) undergoing cardiac surgery are 
at a higher risk of postoperative complications, and the incidence of those complications was 
higher in patients with LV-EF (≤30%). Among those complications is PCS-AKI. 
However, in our study, patients with LV-EF ≤30 showed a slight increase in the development 
of PCS-AKI than those with a higher LV-EF, with a percentage of 15.15% and 12.5%, 
respectively. 
This was not a marked difference to the previous studies; our explanation for this was that not 
all our patients had undergone recent echocardiography as many were emergency patients. 
Therefore, we had to use the most recent echocardiograph to register their LV-EF, which in 
many patients was few months before the surgery and did not reflect the preoperative LV-EF, 
which could have deteriorated more before the surgery in those critically ill patients.  
 
(6) Myocardial infarction (MI) in less than three weeks was mentioned in 2006 by 
Mehta et al. and the following studies (20,23,24,32-36) as a risk factor for PCS-AKI. 
In our study, we found a marked increase in the incidence of PCS-AKI in patients with recent 
MI within 48 hours before surgery, with a percent of 28%, while patients without MI had a 
PCS-AKI percent of 15%. 
However, acute myocardial infarction (AMI) is well known to be a risk factor for AKI, with 
or without any operation, as in the study by Sun et al.(140). Here, a total of 1371 adult 
inpatients with AMI were studied, of which 410 (29.9%) developed AKI after the injury. 
They also stated that decreased baseline renal function, increased fasting plasma glucose 
(FPG) and the use of diuretics were common independent risk factors of AKI after AMI.  
 
(7) Cardiogenic shock (CS) was mentioned in 2006 by Mehta et al. as a risk factor for 
PCS-AKI. In our study, we found a marked increase in the percentage of PCS-AKI when a 
patient had suffered a cardiogenic shock before the operation, where the incidence of PCS-
AKI for patients with cardiogenic shock and those without was 50% and 14.2%, respectively, 
which is significantly higher by more than three and a half times.  
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According to other studies, CS is a well-known risk factor for AKI with or without operation, 
as in the study by Tarvasmäki et al.,(141) where 154 patients with cardiogenic shock without 
any operation were studied in a prospective multicentre CardShock study analysis. AKI was 
defined and staged according to the KDIGO criteria by creatinine (AKI SCr) and/or urine 
output (AKI UO). CysC-based AKI (AKI CysC) was defined similarly to AKI SCr. Changes 
in haemodynamic parameters were assessed over time from baseline until 96 h. The incidence 
of AKI was: AKI SCr 31%, AKI UO 50%, and AKI Cysc 33%. Moreover, the 90-day 
mortality was 38%. 
Zhongguo et al. (142) investigated 172 patients admitted to the general hospital of PLA from 
1993 to 2003 with the diagnosis of AMI or unstable angina in a state of CS to study the 
relationship between early AKI and the prognosis of patients with CS after MI. In total, 31% 
(51 patients) developed AKI within 24 hours after the onset of shock. In-hospital mortality in 
patients with and without AKI was 90% (46/51 cases) and 56% (68/121 cases), respectively. 
 
(8) IABP was mentioned in both Thakar et al., Wijeysundera et al. RRT prediction scores 
as a risk factor. In our study, we found that 80% percent of patients who needed IABP 
preoperatively had developed PCS-AKI, which is a significant high percent. 
Our patients were divided into four levels according to the preoperative cardiopulmonary 
stability condition and the measures required to stabilise them; those four levels were: stable 
without circulatory system medication; stable with a minimal dose of circulatory system 
medication; stable with a high dose of circulatory system medication; and stable with IABP. 
The percent of developing PCS-AKI was as follows: 13%, 32%, 55% and 80%, respectively.  
That means that the more a patient is preoperative cardiopulmonary unstable, the more likely 
to develop PCS-AKI. 
However, in our study, and those of Thakar and Wijeysundera, IABP use showed that patients 
were haemodynamically unstable preoperatively rather than the use of IABP itself being a risk 
factor.  
In many recent as well as old studies, there was marked evidence that preoperative 
prophylactic use of IABP was a successful measure to reduce the risk of PCS-AKI, as in the 
study by Wang et al.(143) in 2016 by The Society of Thoracic Surgeons. This was the first 
meta-analysis to demonstrate significant beneficial effects of preoperative prophylactic IABP 
on renal function in high-risk patients undergoing CABG.  
In this meta-analysis, they investigated the effects of preoperative prophylactic IABP on 
postoperative renal function and short-term death of high-risk patients, and They found that 
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preoperative prophylactic IABP use decreased the incidence of PCS-AKI and short-term 
mortality and significantly reduced the need for PCS-RRT by up to 82% compared with high-
risk patients without the procedure.  
 
(9) Previous cardiac surgery was mentioned as a PCS-AKI risk factor in all prediction 
scores by Thakar et al., Mehta et al. and Wijeysundera et al. as well as the following 
studies(20,23,24,32-36). In our study, we found that previous cardiac surgery is a risk factor for 
PCS-AKI, as patients who underwent previous cardiac surgery have a higher incidence of 
developing PCS-AKI than those without, with an incidence ratio of 25.4%:14%. 
 
(10) Emergency surgery showed a higher incidence of PCS-AKI of 32.6% in our study in 
comparison with the urgent operation indication of 14.56% and elective operation indication 
of 9.46%; we explained that by the smaller time available to bring those critically ill patients 
to a haemodynamically stable state before the surgery. 
In the RRT prediction scores of Thakar et al. and Wijeysundera et al., an emergency 
indication for cardiac surgery was considered to be a risk factor for PCS-AKI.  
In the Thakar study, those patients who had an emergent indication for surgery showed a 
higher incidence of the requirement of PCS-RRT (11.2%) than those without, who showed an 
incidence of 2.9%. 
 
(11)  Surgery type (CABG/ valve replacement surgeries) was considered to be a PCS-
AKI risk factor by the three different RRT prediction scores, as well as in other 
studies(20,23,24,32-36). 
In our study, the primary operation was ascending aorta and aortic arch replacement surgery. 
However, we studied whether a superimposed CABG or valve surgery is a risk factor for 
PCS-AKI or not. 
In case of a superimposed CABG surgery, there was no marked difference on the influence of 
PCS-AKI in patients who had an additional CAPG surgery and those who did not, with 
results of 17.2 % and 13.03%, respectively. 
However, in case of a superimposed valve surgery (especially aortic valve), in contrast to 
what has been published in the aforementioned studies and prediction scores, we found that 
superimposed valve surgery reduced the incidence of PCS-AKI, where the level of PCS-AKI 
being reduced from 18.07% without any valvular surgery to 11.27% with valvular surgery. 
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This regression in PCS-AKI after the superimposed valvular surgery (especially the aorta 
valve) can be hypothetically explained by the improvement in LV-EF and cardiac output after 
the surgery with increasing organ as well as kidney perfusion, resulting in reduced prerenal 
causes of AKI.  
Chaliki et al. (144) stated that patients with severe aortic regurgitation (AR) and significantly 
lower LV-EF had a marked LV-EF improvement postoperatively and that most patients who 
survived the surgery enjoy a long postoperative survival without the recurrence of heart 
failure after aortic valve replacement (AVR); thus they should not be denied the benefits of 
AVR. 
 
(12) Peripheral arterial disease (PAD) was not involved in the RRT prediction scores but 
other studies such as in Kheterpal et al.(145) and in almost all studies (20,23,24,32-36) that analysed 
risk factors of PCS-AKI. However, we found only a slightly higher incidence in patients with 
PAD who developed PCS-AKI than patients who did not, with a percentage ratio of 
16%:14.7%.  
We explain that slight increase by a gap of missed data during the history taking as not all 
patients know whether they have PAD or not as it is not a clinically evident disease like 
hypertension or DM where every patient knows about them. 
Therefore, in our retrospective study, where we had no personal contact with patients, but 
only contact with their folder and data, we could not collect enough information about PAD. 
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5. Conclusion : 
1. The data obtained from our analysis outlined the predictive role of longer moderate 
HCA and CPB times and perioperative blood transfusion for AKI after ascending aorta and 
aortic arch replacement surgery. The complex multifactorial pathophysiology plays an 
underlying prognostic role regarding the outcome for this life-threatening complication and 
requires more focused clinical trials to illustrate the contradicting results from the previous 
analyses regarding the causing pathophysiology. 
 
2. The incidence of AKI after ascending aorta and aortic arch replacement surgery using 
moderate HCA and CPB is approximately 15 %. 
 
3. AKI after ascending aorta and aortic arch replacement surgery increases the mortality 
rate more than six times, and the ICU stay more than three times. 
 
4. Gender, COPD and superimposed CABG surgery are insignificant risk factors for 
PCS-AKI. DM (specially insulin dependent), preoperative chronic kidney disease, recent 
myocardial infarct, preoperative cardiogenic shock, cardiopulmonary instability condition, 
previous cardiac surgery, emergent surgery and  superimposed aortic valve surgery (indirectly 
proportion) are all significant risk factor for PCS-AKI and can be used as predictive variables 
in the future postoperative AKI prediction scores. LV-EF and PAD need more focused 
clinical trials to determine their significance to PCS-AKI 
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